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ABSTRACT OF THE DISSERTATION
Taspase1 is a non-oncogene mediator of tumorigenesis and maintenance
by
David Yuan-Sou Chen
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2012
Asst. Professor James Hsieh, Chairperson
The clinical success of oncogene-targeted therapies substantiates the continued reliance of
certain cancers upon the continued function of apical oncogenes involved in its genesis—a
phenomenon known as “oncogene addiction.” Though this shift from non-targeted, cytotoxic
therapies offers new hope to patients, resistance to oncogene inactivation often remains an
eventuality, and it is clear that further investigation is required to more effectively battle cancer
using alternative therapeutic targets. Our studies on Taspase1 (threonine aspartase 1) reveal its
role in coordinating cellular proliferation and apoptosis in cancer. Loss of Taspase1 by shRNAmediated knockdown decreased cellular proliferation in a diverse set of cancer cell lines,
including glioblastoma, melanoma, lung, breast, colon, and prostate, as well as increased
sensitivity to death stimuli in melanoma and glioblastoma. Taspase1 loss impedes proliferation
via up-regulation of the Cyclin dependent kinase inhibitor p27 and destabilizes the anti-apoptotic
BCL-2 family member MCL-1. Decreased levels of MCL-1 in glioblastoma and melanoma due to
Taspase1 loss sensitizes these cells to a variety of apoptotic stimuli, including anoikis, DNA
damaging agents etoposide and doxorubicin, and to a targeted inhibitor of BCL-2 family proteins,
ABT-737.

We found that Taspase1 is over-expressed in multiple primary human tumors,

including glioblastoma and melanoma, suggesting that Taspase1 is relevant to tumorigenesis in
humans and that its inhibition could be clinically useful.

In vitro examination of tumorigenic clones selected by their ability to form colonies in soft agar
revealed an increase in Taspase1 expression compared to the unselected pool of MEFs
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transduced by defined oncogenes, suggesting an increased reliance on Taspase1 in the process
of tumorigenic transformation. Yet, we demonstrate that Taspase1 is not an oncogene, and
therefore, Taspase1 better fits a new class of cancer targets—the subordinate cellular machinery
of oncogene-driven processes.

Dependence on this machinery was recently termed “non-

oncogene addiction.” Taspase1 loss can sensitize cancer cells to both cytotoxic agents as well
as oncogene-targeted agents, suggesting that inhibition of the non-oncogene addiction protease
Taspase1 can complement traditional therapies.

Through high throughput screening, we have identified a noncompetitive, small molecule inhibitor
of Taspase1, named TASPIN-1, which inhibits Taspase1 in vitro and in cell culture. Murine
fibroblasts treated with TASPIN-1 exhibit decreased proliferative capacity, while also
demonstrating molecular characteristics similar to those observed with the acute, genetic loss of
Taspase1.

TASPIN-1 treatment exerts specific cytotoxicity in human breast cancer and

glioblastoma cells that have high expression of Taspase1. Additionally, TASPIN-1 treated mice
bearing U251 human glioblastoma xenografts exhibit tumor regression while the mice tolerated
short term treatment relatively well. This suggests that pharmacological inhibition of Taspase1 is
of potential therapeutic benefit in the treatment of cancer patients.
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Chapter 1
Oncogenesis, tumor suppression, and Taspase1
1.1 Cancer is a balance between oncogene signaling and suppressed tumor
suppression
1.2 Addiction to oncogene signaling pathways in cancer
1.3 Taspase1 is an evolutionarily conserved threonine protease required for
proper embryonic development and cellular proliferation

1.1 Cancer is a balance between oncogene signaling and suppressed tumor suppression

Cancer phenotypes codified
Cancer is a phenotypic manifestation of genetic and epigenetic alterations that are adaptive for
the cell but maladaptive, ultimately, for the host. Cellular alterations that give rise to cancer are
multitudinous, particularly between cancers of different tissue origins but also within the same
cancer subtype.

Despite the diversity of molecular alterations, the phenotypic expression of

malignancy has been codified into discreet hallmarks, including the ability to propagate
independent of growth factor signaling, resistance against cell death, limitless replicative
potential, insensitivity to growth-inhibitory signals, sustained angiogenesis, and metastasis
(Hanahan and Weinberg, 2000). It seems, then, that the common goal of these traits, whether
intrinsic to the cancer cell or extrinsic, lies in support for the continued potential for deregulated
growth and survival of cancer, except in metastasis.

Though successful metastasis—from

migration from the primary tumor to intravasation and survival in the blood, extravasation, and
survival in the end organ—is not of prima facie benefit to the malignant cell, the fact is that at
terminal stage, cancers typically exhibit metastatic character. One might hypothesize, then, that
the ability to metastasize is merely an incidental manifestation of alterations that were selected for
on the basis that they are critical to tumor growth. Recent evidence suggests that this is indeed
the case in breast cell lines which depend on a set of genes to support tumor growth as well as
vascular remodeling (Gupta et al., 2007). It is increasingly clear that the common theme to these
phenotypic hallmarks of cancer, then, is the molecular alterations that underlie them. These
alterations are typically classified in two groups—genetic or epigenetic changes in certain genes
drive various aspects of oncogenic processes, while the loss or alteration of function of other
genes required for cellular homeostasis facilitates the oncogenic transformation processes.
These genes are known as oncogenes and tumor suppressors, respectively, and they are of
critical importance to tumorigenesis and tumor maintenance. Yet, this body of work demonstrates
that Taspase1, which is not an oncogene, is also of critical importance to tumor maintenance.

2

Experimental determination of oncogenic potential
The genetic origins of cancer had been postulated by Theodore Boveri in conclusions drawn from
his work on sea urchins:

A malignant tumor cell is—and here again I take up the ideas of
Hansemann—a cell with a specific abnormal chromosome constitution. (Harris,
2008)

And of proto-oncogenes:

However, the hypothesis that there are chromosomes that stimulate cell
multiplication is also compatible with our proposal.

In this view, cell division

would take place when the operation of the stimulatory region of the chromatin,
normally too weak, is enhanced by some active agent. The unrestrained
proliferation of malignant tumour cells would then be due to a permanent excess
of these stimulatory chromosomes. (Harris, 2008)

Though these ideas were introduced in 1914, they had remarkable bearing on the ensuing
discovery of oncogenes, illuminated by much work done in retroviral oncogenesis, which was
subsequently extended to cellular oncogenes (Bishop, 1983).

Many other oncogenes were

identified through a combination of retroviral insertional mutagenesis as well as transfection of
tumor-derived DNA into the immortalized murine fibroblast line NIH/3T3. This, notably, led to the
discovery of the human RAS oncogene from bladder cancer (Shih and Weinberg, 1982), formally
linking the previous retroviral oncogene work with the establishment of human cellular oncogenes
(Der et al., 1982; Parada et al., 1982; Santos et al., 1982). The importance of oncogenic RAS
was substantiated by later findings that human tumors bear RAS mutations primarily in codons
12, 13, or 61, rendering its GTPase ability constitutively active. RAS was found to be mutated in
a wide spectrum of cancers, with the highest frequency in exocrine pancreas (80% bear KRAS
mutations), though many other tumor types also exhibit a high frequency of RAS mutation,
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including lung, colon, and thyroid adenocarcinoma, as well as NRAS mutations in myeloid
leukemias (Bos, 1989).

RAS was found to be regulated by upstream factors like receptor tyrosine kinases, which are
known to be oncogenes as well, including the epidermal growth factor receptor (Kamata and
Feramisco, 1984; Mulcahy et al., 1985) and the related HER2/neu. Both receptors were defined
as oncogenes by their ability to cause morphological transformation of NIH/3T3 cells as well as
their ability to confer anchorage independent growth to these cells in soft agar assays and tumor
formation when allografted in immunodeficient mice (Di Fiore et al., 1987; Hudziak et al., 1987;
Velu et al., 1987) . In these studies, soft agar growth correlated well with tumor formation upon
injection into mice likely because soft agar growth reflects many of the growth and survival
advantages acquired in the transformation process.

This includes the ability to survive

independently of signals provided by ligation of homotypic and heterotypic adhesion receptors,
without which typically initiates a physiological death stimulus known as anoikis (Frisch and
Francis, 1994). Such a strong correlation—that soft agar growth always correlates with in vivo
tumor growth—from a seemingly simple assay belies the complexity of oncogene signaling and
the transformed phenotype. Indeed, RAS provides signals to regulate cellular proliferation, death
and survival, protein translation, and cellular motility through its multiple effector pathways RAF,
RAL-GDS and PI3K (Downward, 2003; Malumbres and Barbacid, 2003).

Despite the complexity of RAS signaling alone and the current knowledge that upstream growth
factor

signals

regulate

more

proto-oncogenes

than

just

RAS

(for

example,

the

phosphotidylinositol-3-kinase, PI3K, proto-oncogene), it has been shown that activated RAS
alone cannot transform primary murine fibroblasts. Rather, at least two oncogenic changes are
necessary for murine transformation.

Additionally, these alterations must be complementary

(Land et al., 1983), as RAS alone can interact with other oncogenic pathways, including the direct
activation of the PI3K pathway (Rodriguez-Viciana et al., 1994; Sjolander et al., 1991).
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RAS and MYC comprise one such pair of complementary oncogenes (Land et al., 1983). MYC is
a strongly mitogenic oncogene and has a very short halflife, while co-expression of activated RAS
can stabilize MYC levels.

This results in MAPK dependent phosphorylation of MYC and

subsequent E2F2-mediated transcription and Cyclin E/cdk2 activation, which leads ultimately to
S-phase entry (Leone et al., 1997; Sears et al., 1999; Sears et al., 2000). Cooperation between
MYC and RAS, however, extends beyond stabilization of MYC and enhanced proliferation driven
by oncogenic RAS and MYC.

Oncogenes elicit tumor suppressive signals
Three key barriers to tumorigenesis are irreversible growth arrest (senescence), cell death, and
differentiation. Deregulation of proto-oncogenes like MYC and RAS enhance the tumorigenic
capabilities of the nascent cancer cell; however, tumor suppressive mechanisms can counteract
aberrant, oncogenic signals. Ectopic expression of either MYC or activated RAS alone is not only
unable to transform primary murine cells, the overwhelming oncogenic signaling is actually
deleterious to cells. RAS over-expression induces p53 and p16
and cellular senescence in vitro, and BRAF

E600

INK4A

tumor suppressor expression

expression in melanocytes induces senescence in

vivo, as seen in growth-arrested benign nevi from patients (Michaloglou et al., 2005; Serrano et
al., 1997). The degree to which tumor suppression is elicited seems to be dose-dependent.
Increased MAPK/ERK signaling through RAF activation induces cell cycle arrest that depends on
CIP1

the expression of the Cyclin-dependent kinase inhibitor (CDKI) p21

(Woods et al., 1997).

Titration of oncogenic RAS from a mammary specific promoter reveals that high levels of RAS
signaling in vivo results in transient increases in proliferation in breast epithelium with an ensuing
senescence that is dependent on the INK4A/ARF locus. Low level RAS signaling can escape
p53 activation as well as activation of INK4A/ARF locus, while maintaining enhanced proliferation.
Tumors formed by low-level RAS activation exhibited additional up-regulation of endogenous
RAS as well as evasion of tumor suppressive signals, with p53 loss of heterozygosity and failure
of INK4A/ARF induction (Sarkisian et al., 2007).
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MYC expression, in normal cell cycle, is very tightly regulated as quiescent cells have
undetectable MYC expression; however, upon mitogenic stimuli, MYC is transcribed and can
promote S-phase entry by a variety of mechanisms, including directly activating Cyclin D2 and
KIP1

CDK4, activating CyclinE/ckd2, indirectly down-regulating p27
CIP1

p21

INK4B

and p15

, and directly down-regulating

(Pelengaris et al., 2002a). Supraphysiological expression of MYC, however,

is a potent inducer of apoptosis (Evan et al., 1992)—an effect which relies on the activation of the
p53 pathway through p19

ARF

-mediated stabilization, or the induction of pro-apoptotic BH3-only

molecule BIM (Adhikary and Eilers, 2005). Deregulation of the p53 pathway, or mutation of
residues in MYC that are required for BIM induction, facilitate MYC-induced lymphomagenesis
(Eischen et al., 1999; Hemann et al., 2005). Expression of anti-apoptotic BCL-2 family members
counteracts MYC-induced apoptosis in vitro and facilitates tumorigenesis in vivo (Beverly and
Varmus, 2009; Fanidi et al., 1992; Pelengaris et al., 2002b).

Together, evasion of homeostatic tumor suppressor mechanisms as well as promotion of
tumorigenic signaling is likely to form the basis for the cooperation of oncogenes in oncogene
complementation or with tumor suppressor inactivation.

Though RAS can serve to prevent

apoptosis initiated by MYC over-expression through activation of PI3K/AKT (Kauffmann-Zeh et
al., 1997), in the context of Cyclin D1, D2, and D3 triple deficiency, MYC and RAS are not able to
efficiently complement each other, presumably because an important pro-mitogenic arm is lost.
This suggests that prevention of apoptosis alone is not sufficient to generate tumors and
highlights the necessary function of cooperating oncogenes to both disarm tumor suppressors as
well as provide proliferative signals (Kozar et al., 2004).

Oncogene-induced tumor suppressive mechanisms, like apoptosis and senescence, act as a
barrier for tumor evolution because these endpoints are achievable through the same oncogenic
signals that drive tumorigenesis, depending on the context in which they occur (Lowe et al.,
2004). Though there was little question whether apoptosis was a tumor suppressive mechanism,
senescence was only more recently established as a bona fide antitumor mechanism in vivo
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(Braig et al., 2005; Chen et al., 2005b; Michaloglou et al., 2005). That efficient tumorigenesis
from oncogenes requires complementary deactivation of tumor suppressive pathways illuminates
the intrinsic failsafe mechanisms that have evolved in multi-cellular organisms to maintain
homeostasis. Indeed, it is these intrinsic failsafe mechanisms that we are attempting to engage
when treating cancer.

Revealing the complexity of cancer
The scope of mutations characterized in cancers is rapidly increasing as we overcome
technological hurdles. Massive sequencing projects have recently identified many mutations in
various cancers. Exonic sequencing in lung cancer revealed more than 1,000 somatic mutations
across 623 genes, with 26 occurring at high frequency (Ding et al., 2008). Subsequent efforts to
look globally at mutations encompassed the entire genome in samples from patients with
leukemia as well as in human cancer cell lines.

This has led to some interesting insights

regarding the number of total mutations in cancer cells as well as how many are intragenic versus
intergenic (Ding et al., 2010; Jones et al., 2008; Ley et al., 2008; Parsons et al., 2008; Pleasance
et al., 2010a; Pleasance et al., 2010b). In the sequencing of cytogenetically normal M1 AML
(~10% of all cases of AML), the number of mutations in gene coding regions that were nonsynonymous and unique to the tumor was surprisingly few—10 mutations, of which the majority of
genes had no described function in AML pathogenesis. Furthermore, not all of the mutated
genes were detectably expressed in the tumor (Ley et al., 2008). However, the total tumorspecific single nucleotide variants (SNVs) in intergenic sequences was on the order of tens of
thousands, and using normal skin as a control renders germline predisposition mutations virtually
undetectable. Though studying the gene-coding mutations is likely to have the highest yield in
the short term, these studies highlight the intricacy of how one determines which mutations drive
oncogenesis and which ones are incidental; in short, it is possible that nongenic mutations play a
critical role in tumorigenesis. These issues will likely be addressed as sequencing and analysis
technologies advance, and when all mutations in all tumors can be catalogued.
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With this unprecedented detail in resolving genetic mutations in cancer, it is increasingly clear
that key drivers are still few within a tumor, at least those involved in gene coding regions, though
the variety of possible drivers may be large between tumor types. Based on age and incidence
statistics, it is estimated that common adenocarcinomas, including breast, colon, and prostate,
require 5-7 rate limiting events, while hematological malignancies may require fewer changes
(Stratton et al., 2009). Indeed, knowledge of oncogene and tumor suppressive functions has
made it possible to rationally generate tumors with a minimal set of defined oncogenes in human
cells (Hahn et al., 1999; Hahn and Weinberg, 2002). Concordantly, recent mutational analysis of
gliomas suggests that three critical signaling pathways are typically altered in brain cancers,
including receptor tyrosine kinases (RTKs) and the p53 and Rb tumor suppressor pathways
(Network, 2008). With the implication that relatively few pathways are deregulated in each cancer
type, and hence dependence on these limited pathways for the maintenance of tumor
phenotypes, it seems that targeting one or a few of these pathways would be an effective way to
kill cancers.

1.2 Addiction to oncogene signaling pathways in cancer

Persistent oncogenic signaling is required for maintenance of tumor phenotypes
The initial discovery of oncogenes spurred a wave of continued discovery of important factors
involved in the initiation of tumorigenesis. The prescient words of J. Michael Bishop indicated
that

…cellular oncogenes are involved in tumorigenesis, whatever its proximal cause.
Some of these genes may serve to initiate the genesis of tumors, some to
sustain the final neoplastic phenotype, some may serve either purpose in
different contexts.

Cellular oncogenes appear not to be tumorigenic in their

native state; they must either be activated to abnormal levels of expression, or
mutated so as to change some aspect of their function (Bishop, 1983).
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At the time it had not been demonstrated that propagation of the tumor required persistent
oncogenic signaling. Since then, however, it has been demonstrated that in various contexts,
cancers depend on the continued function of apical oncogenes—a phenomenon termed
“oncogene addiction” (Weinstein, 2002). The earliest evidence of oncogene addiction involved
the targeted inhibition of the ERBB2 receptor tyrosine kinase in breast cancer.

Antisense

oligonucleotide-mediated down-regulation of ERBB2 inhibited proliferation in breast cancer cell
lines that had amplified ERBB2, but not in cell lines that lacked this amplification (Colomer et al.,
1994). Subsequent studies in pancreatic cancer cell lines demonstrated the dependence of the
tumor upon mutated KRAS, while cancer cells that did not have KRAS mutations were insensitive
to KRAS depletion (Aoki et al., 1997).

These in vitro studies suggested that the specific

sensitivity of tumors to the loss of mutant or amplified oncogenes reflected a dependence on the
evolutionary history of the tumor—that the tumor was still dependent on the oncogene that drove
its genesis.

Murine models were generated to demonstrate this phenomenon in vivo. MYC activation in the
skin caused features of cancer, including hyperplasia, dysplasia, and angiogenesis, resulting in a
papillomatosis at around three weeks post-induction. Cessation of MYC induction, however,
caused full regression of skin lesions (Pelengaris et al., 1999).
observed in p16

INK4A-/-

A similar phenotype was

mice with activated RAS expression in the skin. Melanomas developed

after a period of RAS induction but depended on continued expression to maintain the tumor, as
G12V

withdrawal from RAS

caused these tumors to regress (Chin et al., 1999).

Similarly,

withdrawal of MYC in MYC-driven T-cell leukemia caused regression of the tumor with evidence
of differentiation, growth arrest, and apoptosis (Felsher and Bishop, 1999).

The observed dependence of tumors to these oncogenes in vivo spurred the search for means of
pharmacological inactivation of apical oncogenes, resulting in the development of inhibitors for
multiple oncogenes, including HER2 (trastuzumab), BCR/ABL (imantinib), EGFR (gefitinib and
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erlotinib), and VEGFR (sunitinib and sorafenib). These drugs represented a paradigm shift in
cancer therapy, and hence cancer susceptibility to oncogene inactivation was dubbed the
“Achilles heel” of cancer (Weinstein, 2002). Despite the successes of these therapies, none of
these drugs represent a cure for the cancers that they treat. Because of the additional selection
pressure from treatment, clones resistant to treatment emerge, whether it is by mutation of the
targeted kinase (for example, drug resistance mutations that are frequently observed in BCR/ABL
and EGFR in relapsed tumors), or whether tumor suppressive pathways, like p53, are inactivated,
or whether the oncogene addiction shifts its burden to alternative oncogenes (Weinstein and Joe,
2008). Indeed, in a model of MYC-driven breast tumorigenesis, inactivation of MYC caused
regression of tumors; however, tumors relapsed often bearing KRAS2 mutations, which are
known to cooperate with MYC in tumorigenesis (Boxer et al., 2004). Similarly, in human tumors
engineered from 293 kidney epithelial cells, RAS-induction caused rapid tumor formation that was
reversible upon de-induction of RAS; however, tumor maintenance could be enforced by the
activation of the PI3K pathway in the absence of RAS (Lim and Counter, 2005). These studies
suggest that initiation of oncogenesis likely causes a rewiring of cellular circuitry that, even in the
single oncogene MYC-driven tumors, retains many pre-malignant changes, making subsequent
oncogenesis easily achievable. The plasticity of these pathways indicates that we must find
alternative modalities to successfully eradicate cancers.

Latent tumor suppressor networks remain functional
One of these modalities relies, like oncogene addiction, on exploiting the evolutionary history of
the tumor.

In many tumors, inactivation of the tumor suppressors like p53 are critical to

tumorigenesis since p53 responds to oncogenic stress by causing cell cycle arrest, differentiation,
apoptosis, and senescence (Vousden and Lu, 2002). Roughly 50% of tumors inactivate p53 by
mutation, thus compromising its tumor suppressive ability; however, whether the tumor
suppressive effector pathways of p53 remain intact was not known until relatively recent reports
demonstrating the effects of p53-restoration in vivo. Activation of p53 in Eμ-MYC driven lymphoid
tumors caused widespread apoptosis of lymphoma cells (Martins et al., 2006).

10

Similarly,

autochthonous lymphomas—those spontaneously arising from p53-null mice—and sarcomas are
sensitive to p53 re-introduction. Though lymphomas typically responded by initiating cell death,
sarcomas underwent senescence, reflecting an underlying difference in the molecular circuitry
between the different cancer types (Ventura et al., 2007). A third report also demonstrated a
G12V

primarily senescence-mediated tumor suppression for transplanted RAS

-induced liver tumors

upon p53 reactivation (Xue et al., 2007).

Together, these studies suggest that though p53 is inactivated in the course of tumorigenesis, the
simple re-introduction of p53 expression is enough to drive its tumor suppressive functions. This
suggests that both the oncogenic signaling that drives p53 as well as the downstream effector
mechanisms are largely intact and that re-activation of suppressed tumor suppressive programs
is a tractable anti-cancer strategy.

Taspase1 regulates the expression of oncogenes and tumor suppressors
The clinical success of oncogene-inactivating therapies validates the biological concept of
oncogene addiction, while re-introduction of tumor suppressors is a promising new avenue for the
development of novel therapies. Indeed, antagonists of MDM2, an E3-ligase responsible for p53
degradation, have shown pre-clinical promise (Vassilev et al., 2004). Both oncogene addiction
and tumor suppressor sensitivity are important therapeutic concepts, and at the outset of this
present work, we established that Taspase1 regulates the expression of core cell cycle
INK4A

components Cyclin E as well as p16

, which are oncogenes and tumor suppressors,

respectively (Takeda et al., 2006b). This uniquely places Taspase1 at the hub of both pathways.
Whether Taspase1, is required for maintenance of tumors, and hence, whether Taspase1 could
serve as a pharmacological target for cancer therapy, is the question we will address with this
work.
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1.3 Taspase1 is an evolutionarily conserved threonine protease required for proper
embryonic development and execution of the cell cycle

The protease Taspase1 (threonine aspartase 1) is a threonine nucleophile endopeptidase
composed nearly in its entirety of an asparaginase type II homology domain (Pfam PF01112).
This family of enzymes includes L-asparaginase, which converts L-asparagine to L-aspartate by
hydrolysis of the side chain amide bond. Interestingly, Taspase1 participates in proteolysis of the
peptide bond following specific aspartate residues with the consensus peptide sequence
QXD/GXDD, thereby initiating a new class of proteases harboring the asparaginase type II
homology domain.

Taspase1 is translated as a 420 amino acid, 50kDa proenzyme which

undergoes auto-proteolytic maturation to generate 28kDa and 22kDa α and β subunits,
respectively which form stable dimers and finally heterotetramers with enzymatic activity from the
β-subunit N-terminal threonine nucleophile.

Taspase1 was purified as the enzyme responsible for processing the protein product of the
human homologue of Drosophila trithorax, the mixed lineage leukemia (MLL) transcriptional
regulator, which is proteolyzed at two distinct sites, generating 320kDa N-terminal and 180kDa Cterminal fragments. Proteolyzed MLL fragments form stable heterodimers which localize to the
nucleus where MLL complexes maintain proper Hox gene expression (Hsieh et al., 2003a; Hsieh
et al., 2003b; Yokoyama et al., 2002). MLL functionally antagonizes polycomb group proteins at
Hox loci in order to properly define segmental identity.

Though MLL is not known to have

sequence-specific DNA binding capacity, it is able to associate with other transcription factors
and regulate chromatin structure through histone methylation via its C-terminal SET domain as
well as with other epigenetic marks, whether by intrinsic ability or by virtue of cooperation with coactivators or repressors (Milne et al., 2002). Targeted disruption of a single MLL allele in mice
results in overt loss of segmental identity with bi-directional homeotic transformations, while biallelic loss results in mid-gestational embryonic lethality (Yu et al., 1995).
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MLL is deregulated in blood cancers
Aside from its role in development, MLL is involved in at least 60 different in-frame translocations
at chromosome 11, between its N-terminal 1400 amino acids and various translocation partners.
These translocations typify certain hematological malignancies, particularly infant leukemias and
leukemias secondary to treatment with DNA-damaging chemotherapies such as topoisomerase II
inhibitors. It is estimated that up to 10% of blood disorders, including acute myeloid leukemia
(AML), acute lymphocytic leukemia (ALL), biphenotypic leukemias, and myelodysplastic
syndromes (MDS) harbor rearrangements of the MLL genomic locus, 11q23 (Dimartino and
Cleary, 1999). The mechanism by which MLL rearrangements cause leukemia is a matter for
debate, though it has been suggested that leukemogenesis depends on effector functions of the
reciprocal translocation partner, which remain largely uncharacterized (Ayton and Cleary, 2001).

A common feature, however, between various MLL translocations is the retention of the first 1400
amino acids of MLL. Whether the oncogenic properties are due to MLL effector function, fusion
partner gain of function, or haploinsufficiency of the translocation partner is unclear; however, in
many fusions, the leukemogenic potential of MLL translocations depends on intact transactivation
ability of the fusion protein.

Surprisingly, an MLL-β-galactosidase fusion knock in promotes

leukemic transformation, which complicates understanding the underlying mechanism as it
deemphasizes the effector function of the fusion partner (Dobson et al., 2000).

Besides MLL translocations, two other forms of leukemogenic MLL alterations exist—partial
tandem duplication (PTD) of MLL exons and PHD1 domain deletions in exon 8. Given that
leukemias bearing these mutations form in the absence of MLL translocations suggests that
alteration of MLL function is ultimately responsible for leukemogenesis (Ayton and Cleary, 2001),
though other evidence suggests that translocation partners require the intact function of both MLL
as well as the translocation partner (Slany et al., 1998).
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Evidence from our lab indicates that stabilization of MLL in fusion proteins usurps a cell cycledependent, biphasic expression pattern of MLL seen in normal cells. MLL accumulates in G1/S
and G2/M cell cycle phase boundaries and are tagged for proteasomal degradation in S-phase
and mitosis by SCF

SKP2

and APC

CDC20

, respectively. Loss of this biphasic expression results in a

G1/S phase block in the case of MLL deficiency, or an intra-S-phase block in MLL overexpression. Surprisingly, MLL leukemic fusions resulted in persistent, moderate expression of
MLL and consequent deregulation of cell cycle checkpoints (Liu et al., 2007). This suggests that
part of a unifying mechanism for MLL fusion-mediated leukemogenesis is the evasion of cell cycle
checkpoints normally elicited by MLL deregulation.

Despite the importance of MLL in certain leukemias, Taspase1 regulated MLL cleavage may not
have an important role in regulating the MLL fusion protein in leukemogenesis per se, since
leukemic fusions do not retain the Taspase1 consensus cleavage site. However, Taspase1 may
be of importance in MLL-fusion leukemias as a more general regulator of MLL function,
particularly in cell cycle, as well as a regulator for functions subordinate to its other substrates.

Loss of Taspase1 disrupts MLL function in development and the cell cycle
Taspase1 knockout mice exhibit homeotic transformations consistent with abberant segmental
identification due to alteration of MLL function, including a broadened anterior arch of the atlas,
posterior transformation of C7 cervical vertebra to T1, anterior transformation from T8 to T7,
among others (Takeda et al., 2006b). MLL non-cleavage results in hypomorphic histone H3
lysine 4 (H3K4) histone methyltransferase activity, which negatively affects its transactivation
capability. Additionally, non-cleavage of MLL may affect its target loci specificity as well as its
ability to complex with key transcriptional co-regulators. Either of these mechanisms could be in
operation in regulating HOX gene expression, as Taspase1 si-RNA mediated knockdown
prevents the maintenance of the 3’ HOXA group gene expression (Hsieh et al., 2003a).
Importantly, though we illustrated the role of MLL proteolysis in developmental patterning, we
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uncovered a distinct and important role for MLL proteolysis in regulation of the cell division cycle,
specifically by regulating E2F-mediated Cyclin expression (Takeda et al., 2006b).

Taspase1 knockout mice in the mixed B6/129 background are typically postnatal lethal, but the
rare survivors exhibit small body size and male infertility reminiscent of Cyclin D1 and Cyclin E
knockout mice (Geng et al., 2003; Sicinski et al., 1995). Orderly progression though the cell cycle
requires the concerted expression of Cyclins D, E, A, and B, which can be inhibited at various
points by upstream Cyclin-dependent kinase inhibitors (CDKIs) p16

INK4A

, p21

CIP1

KIP1

, p27

, and

others (Figure 1). Taspase1-deficient murine embryonic fibroblasts (MEFs) exhibit delayed cell
cycle entry as well as blunted expression of Cyclins E, A, and B.

We demonstrated that

decreased transactivation of Cyclin E was associated with decreased H3K4 methylation at its
promoter, suggesting that the hypomorphic H3K4 methyltrasferase activity from non-cleaved MLL
might directly regulate Cyclin expression. We found that E2F family members, which are the
known transcriptional regulators of Cyclin expression, interact with MLL, suggesting that E2F
family transcription factors direct MLL to Cyclin promoters to promote their full expression.
Taspase1 deficient MEFs also exhibited increased p16
cell cycle defect, as p16

INK4A

INK4A

expression, further compounding a

sh-RNA knockdown could rescue, to some extent, the Taspase1-null

proliferative defect (Takeda et al., 2006b).

The contributions of other Taspase1 substrates
To dissect the contribution of MLL non-cleavage to the Taspase1-null phenotype, knock-in mice
bearing non-cleavable alleles (nc) of MLL1 and MLL2 were generated.
MLL1

nc/nc

;MLL2

nc/nc

MEFs from

embryos exhibited a milder proliferative defect than Taspase1

-/-

MEFs,

suggesting that non-cleavage of other Taspase1 substrates may contribute to this defect.

The α/β subunit of general transcription factor TFIIA was shown to be proteolytically processed at
a QVDG motif, though it was originally thought to be cleaved N-terminal to an aspartate residue a
few positions downstream. It was later discovered that the protease responsible for cleavage
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after the P1 aspartate was Taspase1 (Hoiby et al., 2004; Zhou et al., 2006). Similarly, a paralog
of TFIIA, ALF, which is specifically expressed in the testis, is also proteolyzed at a site consistent
with a consensus site for Taspase1 cleavage (Figure 4.1). Though the cleaved form of TFIIA is
the predominant form in cells, the biological significance of this cleavage is still unclear. TFIIA
has been shown to interact with TATA binding protein (TBP) and stabilize its interaction with DNA
at core promoters, yet it is also known to e critical for basal and activated transcription at TATAless promoters, suggesting a function beyond binding TBP (Hoiby et al., 2007).

Cleaved TFIIAαβ is primed for ubiquitination and subsequent proteasomal degradation; yet, noncleavage did not affect TFIIA interaction with TFIIAγ or its ability to associate with TBP or its
ability to handle bulk transcription (Zhou et al., 2006). It has been postulated that cleavage helps
to fine-tune expression levels of TFIIA, and it may be that the interactions between cleaved and
un-cleaved forms of ALF and TFIIA with their respective cofactors increases the combinatorial
diversity of their target promoter specificity or effector functions (Hoiby et al., 2007).

Taspase1 as a cancer therapeutic target
Taspase1 is highly expressed in nearly all tested cancer cell lines from various histological origins
(Takeda et al., 2006b); moreover, Taspase1 is up-regulated in transformed clones MEFs selected
G12V

through soft agar, including those initially transformed by E1A/RAS
G12V

dominant negative p53 (DNP53)/RAS

G12V

, MYC/RAS

, and

(Figure 4.3). Loss of Taspase1 renders MEFs resistant

to transformation by the same oncogene pairs and causes a profound depression in proliferation
rate in unadulterated MEFs compared to those that are Taspase1 wild type. Importantly, loss of
Taspase1 results in the up-regulation of p16

Ink4a

with accordant hypo-phosphorylation of pRb and

down-regulation of Cyclins E, A, and B. Though the MLL-Cyclin axis is an important arm of
Taspase1-orchestrated proliferation program, Cyclin D isoforms are largely unaffected by
Taspase1 loss. This may not be altogether surprising since Cyclin D levels are tightly controlled,
with a halflife of 25 minutes and critical sensitivity to extracellular signals, in a manner different
INK4A

from Cyclins E, A, and B (Sherr and Roberts, 1995) (Figure 1A) . As p16
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can both hinder the

assembly of the regulatory Cyclin D subunit and its catalytic kinase counterparts CDK4 and CDK6
as well as inhibit CyclinD-CDK4/6 holoenzyme activity, the absence of Taspase1 may functionally
inactivate Cyclin D by the de-repression (or the up-regulation) of p16

INK4A

.

Though it is apparent that Taspase1 is critical to orchestrating normal cell cycle progression there
is little known about the phenotypic output of Taspase1 deregulation in a disease context. We
hypothesize that the severe, compound cell cycle defect created by Taspase1 loss strongly
argues that Taspase1 is a good candidate for targeted molecular inactivation as an effective
cancer therapy.

The aim of this work will be address whether Taspase1 is critical to

tumorigenesis and whether it subsequently bears responsibility for maintenance of established
tumors. Answering these questions will be the first step in establishing Taspase1 as a molecular
target for cancer therapy.
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Figure 1. Taspase1 regulates the cell cycle through proteolysis of its substrate MLL
A, Orderly progression of the cell cycle requires Taspase1. B, Taspase1 deficiency can deregulate the cell cycle. Depiction of Cyclin levels is adapted from Figure 1 of Sherr, CJ, 1996.
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2.1. Introduction

Cancer is a state of disease that evolves over years of accumulating genetic and epigenetic
abnormalities that confer an enhanced capacity to proliferate and evade apoptosis, eventually
compromising the host (Hanahan and Weinberg, 2000; Vogelstein and Kinzler, 2004). Although
cancers are the product of complex selection pressures, it has been shown that abrogation of
certain apical oncogenes can effectively inhibit cancer cell growth and prolong patient survival–a
phenomenon termed “oncogene addiction” (Weinstein and Joe, 2008). In accordance with this
concept, molecularly targeted drugs have been developed and successfully utilized in treating
cancer patients, exemplified by the use of imatinib for chronic myelogenous leukemia, erlotinib for
lung cancer, and sunitinib for kidney cancer (Zhang et al., 2009). Despite these recent strides
against cancer, most end-stage cancer patients still succumb to their diseases, highlighting the
urgent need for novel anti-cancer therapeutic strategies. Recently, the “non-oncogene addiction”
hypothesis was proposed based on the heavy reliance of cancer cells on certain non-oncogenes
for their continuous growth and survival, which offers a new class of therapeutic targets that are
not conventional oncogenes (Luo et al., 2009).

Thus far, well-characterized non-oncogene

addiction factors include the 26S proteasome, HSF1 (Dai et al., 2007a), and IRF4 (Shaffer et al.,
2008), which handles the rapid protein turnover, mediates the stress response, and maintains
expression of the MYC oncogene, respectively. The fact that the proteasome inhibitor bortezomib
is effective against multiple myeloma in human patients substantiates this new anti-cancer
therapeutic concept (Adams, 2004).

Uncontrolled proliferation and increased resistance to apoptosis are two cardinal features of
cancer, and consequently, inhibiting cancer cell division and enhancing cancer cell death
constitute two effective anti-cancer therapeutic strategies (Hanahan and Weinberg, 2000; Lowe et
al., 2004).

Cancer cell cycle is typified by constitutively activated Cyclin/CDK complexes,

resulting from either over-expression of Cyclins or down-regulation of CDK inhibitors (CDKIs) that
are oncogenes and tumor-suppressor genes, respectively (Besson et al., 2008; Sherr, 1996). By
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analogy, impaired apoptosis in cancer cells can result from either up-regulation of anti-apoptotic
(such as BCL-2, BCL-XL, and MCL-1) or down-regulation of pro-apoptotic BCL-2 family proteins
(such as BAX, BAK, BIM, and PUMA) (Danial and Korsmeyer, 2004). Targeted anti-cancer drugs
have been developed and are on clinical trials based on these frameworks, and hence continued
elucidation of the molecular control of cancer cell proliferation and cell death should unveil new
anti-cancer targets and offer novel treatment options.

Taspase1 (threonine aspartase 1) encodes a highly conserved 50kD α-β proenzyme which
undergoes intramolecular autoproteolysis, generating a mature α28/β22 heterodimeric protease
that displays an overall α/β/β/α structure (Hsieh et al., 2003a; Khan et al., 2005). Taspase1 is the
only protease within the family of enzymes that possesses an asparaginase_2 (PF01112)
homology domain, while other members, including L-asparaginase and glycosylasparaginase,
participate in the metabolism of asparagine and the ordered breakdown of N-linked glycoproteins,
respectively (Hsieh et al., 2003a).

Taspase1-mediated cleavage follows distinct aspartate

residues of conserved QXD/GXDD motifs (Hsieh et al., 2003b), suggesting that Taspase1
evolved from hydrolyzing asparagine and glycosylasparagine to cleaving polypeptides.

The

cloning of Taspase1 founded a novel class of endopeptidases which utilizes the N-terminal
threonine of mature β subunit to cleave protein substrates after P1 aspartate. Taspase1 was
initially purified as the protease which cleaves MLL to regulate HOX gene expression (Hsieh et
al., 2003a).

Subsequent studies identified additional Taspase1 substrates, including MLL2,

TFIIAα-β, ALF (TFIIAτ), and Drosophila HCF (dHCF) (Capotosti et al., 2007; Takeda et al.,
2006b; Zhou et al., 2006). Collectively, all of the known Taspase1 substrates are nuclear factors
that control gene expression, suggesting that Taspase1 cleaves nuclear factors to orchestrate
genetic programs.

Our prior study of Taspase1-/- mice uncovered a critical role of Taspase1 in cell cycle control
(Takeda et al., 2006b). In the absence of Taspase1, cell cycle is disrupted with decreased
expression of Cyclins, including E, A, and B, and increased expression of CDK inhibitors (CDKIs),

21

including p16, p21, and p27 (Takeda et al., 2006b). Hence, Taspase1 may play a permissive role
-/-

in tumorigenesis, which is supported by the demonstrated resistance of Taspase1

mouse

embryonic fibroblasts (MEFs) to oncogenic transformation induced by MYC, RAS, DNp53, and
E1A. Although the absence of Taspase1 poses a profound roadblock in cancer initiation (Takeda
et al., 2006b), whether Taspase1 is required for cancer maintenance remains unknown. Here,
we demonstrate that Taspase1 is required to maintain a full cancer phenotype and is overexpressed in primary human cancer tissues. Deficiency of Taspase1 in human cancer cells
results in impaired proliferation and enhanced susceptibility to death stimuli. Taspase1 is not a
classical oncogene, yet it enables expression of cancer characteristics; thus, it is better classified
as a “non-oncogene addiction” protease. As proteases are ideal drug targets, small molecule
inhibitors of Taspase1 may be developed for cancer therapy.

2.2 Taspase1 is required for efficient tumor maintenance in vitro

Our prior study demonstrated that Taspase1-/- primary MEFs are defective in proliferation and
thus resistant to in vitro transformation induced by well-characterized oncogene pairs including
G12V

MYC-RAS

G12V

, DNp53-RAS

G12V

, and E1A-RAS

(Takeda et al., 2006b). These data highlight a

critical participation of Taspase1 in cancer initiation, whereas whether Taspase1 has any role in
cancer maintenance remains unanswered. To address this question, we employed a tamoxifeninducible cre-lox system that allows for a precisely controlled genomic deletion of the conditional
“floxed” (f) Taspase1 allele.

Specifically, MYC-RAS-transformed Rosa26-creERT;Taspase1f/-

(R26-creERT;T1f/-) and R26-creERT;T1+/- MEFs were treated with a 6-hour pulse of 500 nM 4hydroxytamoxifen (4-OHT), which efficiently activated creERT fusion to excise the conditional
allele of Taspase1 (Figure 2.1A).

Deletion of Taspase1 in MYC-RAS transformed R26-

creERT;T1f/- MEFs resulted in a profound proliferation block and disruption of colony formation
on soft agar (Figure 2.1 B and C), indicating the requirement of Taspase1 for the proliferation of
transformed cells. Of note, in agreement with the known toxicity of Cre recombinase in MEFs
(Loonstra et al., 2001), the pulse activation of creERT in control, MYC-RAS transformed R26-
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creERT;T1+/-, MEFs generated minor phenotypes in both assays (Figure 2.1 B and C). Taken
together, our data support a permissive role of Taspase1 in cancer maintenance apart from
cancer initiation.

2.3 Taspase1 is not an oncogene

To further define the role of Taspase1 in tumorigenesis, we asked whether Taspase1 functions as
an oncogene. To directly assess the oncogenic potential of Taspase1, we employed two different
sets of in vitro transformation assays that are commonly utilized to characterize newly discovered
oncogenes. First, we stably introduced Taspase1 into NIH/3T3 cells by retrovirus-mediated gene
transduction, and determined the ability of transduced NIH/3T3 cells to grow on soft agar.
Taspase1-transduced NIH/3T3 cells were unable to produce discernible colonies on soft agar,
whereas RAS

G12V

, as a positive control, efficiently rendered anchorage-independent growth

(Figure 2.2 A and Figure 2.7 A). Second, we tested the ability of Taspase1 to work in concert
G12V

with RAS

, MYC, or E1A to transform primary MEFs. Taspase1 was unable to complement

respective oncogenes to induce colony growth on soft agar (Figure 2.2 B and Figure 2.7 B).
Thus, Taspase1 appears not fit the criteria for a classical oncogene despite its requirement for
cancer initiation and maintenance. The fact that Taspase1 is not an oncogene and yet enables
oncogenesis suggests that Taspase1 is better classified as a “non-oncogene addiction” protease.

2.4 Taspase1 is required for inhibition of human cancer cell proliferation

Given the requirement of Taspase1 in murine oncogenesis in vitro, we chose a wide variety of
human cancer cell lines from the well-characterized NCI-60 panel to study the role of Taspase1 in
human carcinogenesis.

Human melanoma (SK-MEL-2), glioblastoma (U251), colon (HT-29),

ovary (OVCAR-3), lung (A549), prostate (PC3), and breast (MDA-MB-231) cancer cell lines,
representing major tissue types of human solid cancers, were examined. The expression of
Taspase1 in these cell lines was determined (Figure 2.3 A). Knockdown of Taspase1 in these
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human cancer cell lines compromised their proliferative capacity but to a varying degree (Figure
2.3 B). Interestingly, cancer cell lines with higher Taspase1 levels appear to exhibit a more
profound proliferation block upon knockdown of Taspase1 (Figure 2.3 B and Figure 2.8), lending
support to the notion that Taspase1 is co-opted by oncogenes to enforce cancer characteristics.
Increased Taspase1 expression in cancer cells likely reflects an inherently elevated dependence
on Taspase1 for maintaining a full cancer phenotype.

The molecular basis underlying the

proliferation defect induced by the deficiency in Taspase1 was further interrogated with a primary
focus on the regulation of Cyclin E, A, and CDKIs–known downstream targets of Taspase1 in the
cell cycle control (Takeda et al., 2006b). Analyses of p16, p21, p27, Cyclin E2, and Cyclin A in
these cancer cell lines revealed that the induction of p27 is most correlative with the growth
inhibition induced by the Taspase1 loss (Figure 2.3 C). For example, PC-3 and MDA-MB-231
cells exhibited minimal growth inhibition upon Taspase1 knockdown, and no induction of p27 was
observed in these Taspase1-knockdown cancer cells. Interestingly, p16 and p21 were induced in
SK-MEL-2 and A549 cell lines, respectively though the role of p27 in inhibiting cancer cell cycle
may dominate over p16 and p21 due to frequent deletions of the p16INK4A/p14ARF locus,
frequent mutation of p53, the upstream activator of p21, and the extremely rare incidence of p27
mutations in human cancers (Besson et al., 2008). Taspase1 regulation of p27 happens on a
transcriptional as well as post-translational level (Figure 2.10).

Taspase1 activates the transcription of Cyclins through MLL proteolysis (Takeda et al., 2006b;
Tyagi et al., 2007). However, we did not observe a reduction of Cyclin E2 or A expression in
these cancer cell lines, suggesting that the Taspase1-MLL axis in regulating Cyclins may have
been disrupted during the development of these cancers. Of note, analysis of known genetic
mutations in oncogenes and tumor suppressors in these cancer cell lines did not identify a causal
mutation explaining the Taspase1 dependence (Table 2.1), highlighting the potential, general
application of Taspase1 inactivation to inhibit cancer cell growth.
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2.5 Requirement for Taspase1 in anoikis resistance

As Taspase1 plays a critical role in sustaining cancer cell proliferation, we investigated whether
Taspase1 is also involved in modulating cancer cell death–another principal mechanism often
deregulated in tumorigenesis. Interestingly, Taspase1 deficiency resulted in a minor increase in
spontaneous apoptosis in both SK-MEL-2 and U251—cells that express high levels of Taspase1
(Figure 2.4 A). The increase in spontaneous apoptosis due to Taspase1 deficiency suggests that
Taspase1 governs a fundamental process in cellular survival and that deregulation of this
process, in the absence of Taspase1, would sensitize these cell lines to further death stimuli.
The initiation of cell death by detachment from its substrata is an important, physiological initiator
of apoptosis, termed anoikis, and the cellular resistance to anoikis constitutes a primary
determinant of metastatic potential. Accordingly, we determined whether the loss of Taspase1 in
U251 and SK-MEL-2 would affect anoikis sensitivity. Taspase1 deficiency sensitized SK-MEL-2
and U251 cells to anoikis, which was not evident in other tested human cancer cell lines except to
a lesser degree in A549 lung cancer cells (Figure 2.4 B).

The degree to which Taspase1-

sustained proliferation and enhanced anoikis resistance contribute to tumorigenesis was further
interrogated with soft agar assays. The ability of cells to form colonies on soft agar is a stringent
in vitro predictor of in vivo tumorigenicity as soft agar imitates tumor microenvironment and
thereby simultaneously assesses cellular proliferation and anoikis resistance. Indeed, Taspase1
deficiency in SK-MEL-2 and U251 cancer cells resulted in reduced colonies on soft agar (Figure
2.4 C). Altogether, our data reveal a novel capacity of Taspase1 in regulating cell death in
human cancers.

2.6 Taspase1 deficiency results in decreased MCL-1 level and increased sensitivity to
chemotherapeutic agents and ABT-737.

Melanoma and glioblastoma multiforme (GBM) are two highly aggressive human cancers that
portend dismal outcomes when presenting at advanced stages. Their increased sensitivity to
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death upon Taspase1 knockdown prompted us to investigate the mechanism by which Taspase1
regulates apoptosis in these cancers. The BCL-2 family constitutes the core apoptotic machinery
which operates at the mitochondrion, controlling cytochorome c release and caspase activation
(Danial and Korsmeyer, 2004). The activator BH3-only molecules BID, BIM, and PUMA directly
activate the apoptotic effectors BAX and BAK, whereas BCL-2, BCL-XL, and MCL-1 inhibit
apoptosis by sequestering BH3s (Figure 2.11 A) (Cheng et al., 2001; Kim et al., 2006; Kim et al.,
2009; Letai et al., 2002; Wei et al., 2001). Based on this framework, we examined the expression
of core regulators of mitochondrial apoptosis in control- or Taspase1-knockdown SK-MEL-2 and
U251 cells, which identified decreased MCL-1 as the common alteration (Figure 2.5 A).
Therefore, Taspase1 may function to maintain the MCL-1 level and thus modulate the apoptotic
threshold in GBM and melanoma (Figure 2.11 B). To examine this hypothesis, we first knocked
down MCL-1 to a comparable level as observed in Taspase1-knockdown cells. When comparing
the propensity of Taspase1- or MCL-1-knockdown cells to undergo anoikis or DNA damageinduced apoptosis, we observed a comparably enhanced apoptotic sensitivity in both U251 and
SK-MEL-2 cells (Figure 2.5 and Figure 2.12). Notably, the Taspase1 deficiency-induced downregulation of MCL-1 is of potential clinical significance. As ABT-737, a specific inhibitor of BCL2/BCL-XL, is ineffective at killing MCL-1 over-expressing cancer cells (Oltersdorf et al., 2005;
Opferman, 2006; van Delft et al., 2006), inactivation of Taspase1 may offer an effective strategy
to sensitize these resistant cancer cells to ABT-737-induced apoptosis. Accordingly, we treated
control- or Taspase1-knockdown U251 and SK-MEL-2 cells with ABT-737 and demonstrated
increased apoptosis in Taspase1 deficient cancer cells (Figure 2.5 C and Figure 2.12 B). In
summary, deficiency of Taspase1 confers sensitivity to apoptosis in GBM and melanoma cancer
cells through down-regulation of MCL-1, suggesting a potential therapeutic benefit from
combining Taspase1 inhibitors with currently-used cytotoxic agents as well as ABT-737 for
cancer treatment.
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2.7 Taspase1 regulates the protein half-life of MCL-1.

The MCL-1 protein level can be titrated through transcriptional, translational, and posttranslational mechanisms, which explains its unusual capacity among BCL-2 family members to
rapidly respond to environmental cues for cell death control (Opferman, 2006). As Taspase1
functions mainly through processing nuclear factors and thus orchestrating transcription, we
determined if Taspase1 directly regulates the transcription of MCL-1. Interestingly, there was no
decrease of the MCL-1 transcript level in Taspase1 deficient U251 and SK-MEL-2 cells (Figure
2.5 D and Figure 2.12 C). Rather, Taspase1 deficiency shortened the protein half-life of MCL-1
from ~1 hour to ~20 minutes in U251 cells (Figure 2.5 E).

Furthermore, treatment with

proteasome inhibitor MG132 prevented the degradation of MCL-1 in both control- and Taspase1knockdown U251 cells. The resultant half-life of MCL-1 is comparable between control- and
Taspase1-knockdown cells upon MG132 treatment, suggesting that Taspase1 sustains the MCL1 protein by enhancing its protein stability.

The control of MCL-1 degradation is complex and context dependent, which at least involves the
E3 ligase MULE, the GSK3β signaling, and the inactivator BH3 NOXA (Chen et al., 2005a; Ding
et al., 2007; Maurer et al., 2006; Zhong et al., 2005). To provide further mechanistic details
regarding how Taspase1 controls the MCL-1 degradation, we determined the expression of
MULE and did not detect an increased transcript level of MULE in Taspase1-knockdown cells
(Figure 5F and Figure 2.12 C). Nor did we detect a difference in transcript of another described
E3-ubiquitin ligase known to regulate MCL-1, β-TRCP, or a stabilizing chaperone for MCL-1,
TCTP (Figure 2.5 F) (Ding et al., 2007; Liu et al., 2005). We investigated whether Taspase1
disrupts GSK3β signaling thereby extending the MCL-1 half-life. Inhibition of GSK3β by TZDZ-8
in Taspase1 deficient cells did not result in increased MCL-1 protein (Figure 2.13). We also
determined the expression of NOXA and did not detect an induction of NOXA protein in
Taspase1-deficient cells to account for the increased degradation of MCL-1 (Figure 2.5A). Taken
together, these data indicate that Taspase1 regulates the MCL-1 protein through a distinct
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proteasome-dependent mechanism that appears not to involve the suppression of MULE
expression, the inactivation of the GSK3β signaling, or the suppression of NOXA expression.
Taspase1 appears to regulate MCL-1 by the recently-described de-ubiquitinase for MCL1,
USP9X at the transcriptional level, resulting in decreased USP9X protein and increased MCL-1
ubiquitination (Figure 2.5 F, G, H) (Schwickart et al., 2010).

2.8 Taspase1 is over-expressed in primary human GBM and melanoma tissues and its
deficiency disrupts tumor growth in a xenograft model.

Our in vitro assays indicate that Taspase1 enables a full cancer phenotype by facilitating cancer
cell cycle progression and suppressing cancer cell death. To probe the in vivo requirement of
Taspase1 in human cancer growth, we performed a tumor xenograft assay using
immunocompromised NOD;scid;IL2Rγ

-/-

mice.

Importantly, loss of Taspase1 significantly

inhibited the growth of U251 tumors in NOD;scid;IL2Rγ

-/-

mice due to a decreased proliferative

index as assessed by Ki67 staining, and increased cell death (Figure 2.6 A, B, and C).
Furthermore, treatment of mice bearing U251 xenografts with ABT-737 resulted in a marked
increase in cell death in Taspase1-deficient tumors (Figure 2.6 C).

Several lines of evidence suggest that Taspase1 is recruited by oncogenes to maintain cancer
characteristics during tumorigenesis. First, our in vitro and in vivo studies indicate that Taspase1
functions as a critical node in the oncogenic network that sustains proliferation and suppresses
cell death. Second, Taspase1 is highly expressed in most of the NCI-60 human cancer cell lines
(Takeda et al., 2006b). Third, there is a positive correlation between the level of Taspase1
expression and the degree of disruption in cancer phenotypes upon its inactivation in examined
human cancer cell lines. Theoretically, Taspase1 may be highly-expressed in certain human
cancers, and based on our data, its over-expression would indicate a favorable therapeutic
outcome upon its inhibition.
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To enable assessment of Taspase1 expression in primary tissues, we established an
immunohistochemistry (IHC) assay using a newly raised anti-Taspase1 monoclonal antibody.
We focused on GBM and melanoma as our cell line data suggested a central for Taspase1 in the
maintenance of these cancers.

Remarkably, Taspase1 is abundantly expressed in primary

human GBM tissues (n = 19), whereas no or weak staining of Taspase1 is observed in adjacent
or control brain sections (n = 13) that mainly consist of astroglial cells–the same cellular origin of
GBM (Figure 2.6B and Figure 2.15). The specificity of Taspase1 staining was confirmed as no
signal was detected when the anti-Taspase1 antibody was pre-incubated with the Taspase1
immunogen (Figure 2.16). Of note, a recent, independent gene expression profiling analysis
demonstrated over-expression of Taspase1 in primary human GBM tissues (Scrideli et al., 2008).

Additionally, Taspase1 is preferentially expressed in melanoma compared to melanocytic nevus
(Figure 2.17).

Similar expression of Taspase1 between melanocytic nevus and adjacent

keratinocytes serves as an internal reference for Taspase1 expression, since normal
melanocytes cannot be histologically differentiated from malignant melanocytes in the same
section. To quantify the preferential expression of Taspase1 in melanoma, we compared the
relative immunoflourescence signal between melanoma and keratinocytes versus that of nevus
and keratinocytes, which confirmed a statistically significant over-expression of Taspase1 in
melanomas (Figure 2.17). In summary, IHC and IF assays established to assess the expression
of Taspase1 in primary human tissues demonstrate the over-expression of Taspase1 in primary,
human GBM and melanoma. This suggests that Taspase1 may have an important role in the
pathogenesis of these human cancers and that it may serve as a new therapeutic target for these
currently intractable diseases.

2.9 Discussion

Taspase1 plays an essential role in regulating embryonic cell cycle, as evidenced by the smaller
body size of Taspase1-/- mice (Takeda et al., 2006b).
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Molecularly, Taspase1 functions to

activate transcription of Cyclin E, A and B, and to suppress that of CDKIs p16, p21 and p27 in
primary MEFs for cellular proliferation.
homeostasis is less clear.

In contrast, the role of Taspase1 in adult tissue

As Taspase1 coordinates the expression of Cyclins and—known

oncogenes and tumor suppressors, respectively—inactivation of Taspase1 may offer a novel
mechanism to inhibit cancer cell proliferation. In agreement with this hypothesis, deficiency of
Taspase1 in human cancer cells impedes proliferation. In contrast to our prior observation that
the loss of Taspase1 has no impact on the baseline cell death of primary MEFs which express
low levels of Taspase1 (Takeda et al., 2006b), GBM and melanoma cancer cells that express
high levels of Taspase1 exhibited increased sensitivity to death stimuli upon Taspase1
inactivation.

Mechanistically, Taspase1 deficiency in U251 and SK-MEL-2 cells resulted in an increased
degradation of MCL-1 via USP9X regulation, accounting for the enhanced death phenotype.
MCL-1 is unique among anti-apoptotic BCL-2 family members as it rapidly responds to external
signals and can be regulated by transcriptional, translational, and post-translational mechanisms
(Opferman, 2006). Regulation of MCL-1 protein turnover is itself complex and implicates multiple
pathways. MULE/ARFBP-1 was the first described E3-ligase required for MCL1 degradation,
though in MULE deficient cells, MCL-1 is still degraded upon initiation of apoptosis, suggesting
the existence of additional mechanisms for MCL-1 degradation (Zhong et al., 2005).

For

example, the PI3K/AKT pathway inhibits GSK3β-mediated phosphorylation of MCL-1 and thereby
prevents β-TrCP-mediated ubiquitylation and proteasomal degradation of MCL-1 (Ding et al.,
2007; Maurer et al., 2006).

Additionally, MCL-1 protein stability can be regulated by direct

protein-protein interactions, as its interaction with NOXA is known to modulate MCL-1 turnover,
and TCTP can stabilize MCL-1 (Chen et al., 2005a; Liu et al., 2005).

How Taspase1 regulates the transcription of USP9X a matter for future study. Nevertheless,
down-regulation of MCL-1 by Taspase1 knockdown in cancer cell lines has important implications
in cancer therapy.

The small molecule inhibitor of BCL2/BCL-XL, ABT-737, is currently
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undergoing clinical trials. Although ABT-737 is quite potent in killing certain types of cancer cells,
it is ineffective against MCL-1 over-expressing tumors due to its inability to inhibit MCL-1
(Konopleva et al., 2006; Oltersdorf et al., 2005; van Delft et al., 2006). Accordingly, Taspase1
inhibitors may synergize with ABT-737 to induce apoptosis in human cancers.

There has been a relatively recent shift in focus from non-specific, cytotoxic therapies to a
targeted approach in cancer treatment, supported by the observation that tumor survival is
dependent on the continued function of the initiating oncogene–a phenomenon known as
“oncogene addiction” (Weinstein, 2002).

Moreover, re-introduction of defective tumor

suppressors can engage intrinsic tumor suppression mechanisms to destroy cancer cells,
suggesting that the intrinsic tumor suppression network present at the inception of tumorigenesis
remains largely intact yet dormant (Lowe et al., 2004).

In the present study, we find that

Taspase1 loss modulates proliferative and death signals through the regulation of the tumor
suppressive CDKIs and the pro-survival MCL-1, respectively, suggesting that Taspase1 functions
as a critical node that when lost, intact tumor suppressive mechanisms can dominate, slowing
cancer cell proliferation and rendering increased cancer cell susceptibility to death stimuli.

Despite its involvement in oncogenesis, when introduced with established oncogenes, Taspase1
failed to enable the survival and growth of MEFs on soft agar. Recent studies have identified
cellular proteins required for tumorigenesis that are non-oncogenes, a phenomenon termed “nononcogene addiction” (Luo et al., 2009). Hence, Taspase1 is better categorized as a nononcogene addiction protease. Factors first described in this paradigm include the master heat
shock response regulator heat shock factor 1 (HSF1) as well as interferon regulatory factor 4
(IRF4). Both are transcription factors that are positioned to regulate broad cellular processes that
are required for normal cellular homeostasis, but upon which tumors have increased
dependence. HSF1 not only relieves proteotoxic stress by regulating heat shock proteins, but
also modulates signaling from other oncogenic pathways, including ERK, and also regulates
protein translation as well as glucose metabolism (Dai et al., 2007a). IRF4 similarly executes a
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broad genetic program that is involved in normal B-lymphocyte activation, but also supports the
oncogenic platform by its regulation of membrane biogenesis as well as metabolic control, cell
cycle progression, cell death, and differentiation (Shaffer et al., 2008). Although the concept of
targeting non-oncogene addiction factors for cancer treatment is novel, this strategy has proven
fruitful with the successful application of the proteasome inhibitor bortezomib in treating certain
human cancers.

Taspase1 is similarly positioned to regulate a broad array of biological functions, including
development, cellular proliferation, and cell death, as all of the Taspase1 substrates described to
date are broad-acting transcription regulators, including TFIIA and MLL.

Although Taspase1

plays a critical role in embryonic development, acute deletion of Taspase1 in mice did not incur
obvious organismal distress and changes in blood counts (data not shown), supporting a potential
application of Taspase1 inhibitors in treating cancers.

Though the mechanisms whereby

Taspase1 is co-opted to promote tumorigenesis remain to be examined, the increased
requirement for Taspase1 in certain cancers represents a possibility for a therapeutic window in
which Taspase1 inhibition can work in conjunction with other forms of targeted and non-targeted
cancer treatments. Taspase1, as a site-specific protease, allows for rational design of substrate
mimetic inhibitors as well as expedient high-throughput screening for potential small molecule
therapeutic leads (Lee et al., 2009). Although targeting the non-oncogene addiction network for
cancer therapeutics is in its rudimentary stage, the successful utilization of this novel strategy is
likely to add effective chemotherapeutic agents to our current armamentarium for combating
cancers.
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2.10 Materials and Methods

Mice and MEFs
+/-

Straight and conditional knockout mice of Taspase1 have been described. Taspase1 mice were
ERT

crossed with Rosa26-cre
crossed with T1

f/+

ERT

mice to generate R26-cre

+/-

;T1

ERT

mice. R26-cre

+/-

;T1

mice were

mice to generate E13.5 primary MEFs. Genotyping for the Taspase1 allele and

the retroviral transduction of the oncogene pairs, MYC plus RAS

G12V

into MEFs have been

described (Takeda et al., 2006b).

Plasmids
Nucleotide 480 of the human Taspase1 cDNA was mutated from T to A to create a silent
mutation that abolished the internal EcoRI site using the QuickChange system (Stratagene). The
Taspase1 was inserted into a murine stem cell virus (MSCV) vector as a BamHI-EcoRI fragment
G12V

downstream of an internal ribosomal entry site (IRES). Human c-MYC, HRAS

and E1A from

adenovirus V early region were PCR cloned upstream of the IRES site using BglII and XhoI to
generate c-MYC-IRES-T1, RAS
G12V

RAS

G12V

G12V

and E1A-IRES-RAS

-IRES-T1, and E1A-IRES-T1.

Constructs for MYC-IRES-

were described previously (Takeda et al., 2006b). Taspase1

RNAi oligos were generated by Oligoengine (Seattle, Washington), annealed and inserted into
the vector pSuperior according to the manufacturer’s protocol. hTaspase1 was targeted using
two independent target sequences (sh-T1 is 5’-GGAAAGCCAAGACTCACAT-3’ and sh-T1#2 is
5’-GCAGTAGATCATGGAATAC-3’), while scrambled shRNA control was acquired from
Oligoengine (5’-GCGCGCTTTGTAGGATTCG-3’).

The target sequence for MCL-1 is (5’-

CCCATCTCAGAGCCATAAG -3’).

Cell Culture, Virus Production, and Retroviral Transduction.
All cancer cell lines were provided by the NCI Developmental Therapeutics Program (Bethesda,
MD) and cultured according to the provided instructions. Amphotrophic retroviruses were
generated by transfection of 293T cells with a helper-free packaging system as described (19).
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Infections were carried out for 48 hours with an 8 μg/mL supplement of polybrene (Sigma, St.
Louis, MO) and subsequently selected for stable integrants in puromycin-containing media.

Soft Agar Assay
5

Cancer cell lines were plated at 10 cells per 6 cm dish in 0.3% agar noble layered on top of a
0.6% agar noble base. Cells were fed every 3 days with media, and after 2-3 weeks, colonies
>0.1mm from 5 low power fields per plate were scored. Soft agar assays for primary MEFs were
performed as previously described (Takeda et al., 2006b).

Anoikis assay
5

Cancer cell lines were detached from their adherent substrata by trypsinization and 10 cells were
plated, in their normal media, per well into 6-well plates coated with 6 mg of Poly-HEMA (Sigma,
St. Louis, MO) to prevent attachment to tissue culture plastic.

Non-adherent and loosely

adherent cells were harvested after three days, trypsinized, and stained with Annexin V-Cy3
(Biovision, Mountain View, CA) and subjected to flow cytometry analysis on a FACSCalibur
cytometer (BD Biosciences, San Jose, CA) to determine viability. Primary MEFs used were
under 3 passages and were cultured in IMDM, supplemented with 20% fetal bovine serum, 2 mM
L-glutamine, 1 mM MEM non-essential amino acids, 1 mM sodium pyruvate, 0.1 mM βmercaptoethanol, and 100 U/ml penicillin/streptomycin (Invitrogen). Primary MEFs were plated at
5

10 cells per well in 2 ml of normal culture media, except that the serum was reduced to 1%, on
Poly-HEMA coated 6-well plates and harvested 24 hours after plating and analyzed for viability as
described above.

Cell cycle analysis
Cancer cell lines with control- or Taspase1-knockdown were stained with propidium iodide and
subjected cell cycle analysis as previously described (Liu et al., 2007).
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Quantitative RT-PCR and Protein Degradation Assay
RNA was harvested from U251 and SK-MEL-2 cell lines using Trizol and first strand synthesis
was performed using Superscript II (Invitrogen, Carlsbad, CA) according to the manufacturer’s
protocols. Quantitative PCR was performed using SybrGreen PCR with an ABI 7300 Real Time
PCR system. Primers sequences used are as follows:

HGNC symbol
BTRC (β-TrCP)
MCL1
HUWE1 (MULE)
USP9X
ACTB
TPT1 (TCTP)
CDKN1B (p27)

5’
3’
5’
3’
5’
3’
5’
3’
5’
3’
5’
3’
5’
3’

Sequence
CAGGATCATCGGATTCCACGGTCAG
TCTACAACATTGACAGCAGCTCGGTG
GCTGCATCGAACCATTAGCAGAAAG
TTGGAGTCCAACTGCATAAACTGGT
CGGCATCTGTACAGTTCCATAGAGC
AATGTTGTAGCCGAGTTAGCAGCG
CCACCTCAAACCAAGGATCAATGAAATG
CTCTCCACTCCATGTTGATTAGGAATAG
CCTGGACTTCGAGCAAGAGATGG
GATCTTCATTGTGCTGGGTGCCAG
CGAAAGCACAGTAATCACTGGTGTCG
GATGTGCTTGATTTGTTCTGCAGCC
GCTAACTCTGAGGACACGCATTTGG
TTTGACGTCTTCTGAGGCCAGG

Protein degradation assays were performed as previously described (Liu et al., 2007).

Antibodies
The polyclonal antibody used to detect Taspase1 was described (Takeda et al., 2006b). Other
antibodies used include BID (Kim et al., 2006), BIM (N22-40, Calbiochem), PUMA (P4743,
Sigma), NOXA (ab13654, AbCam), p21 (sc-397, Santa Cruz), p27 (sc-528, Santa Cruz), p16
(G175-1239, BD Pharmingen), Cyclin E2 (4132, Cell Signaling), Cyclin A (C4170, Sigma), MCL-1
(sc-819, Santa Cruz), BCL-2 (6C8, BD Pharmingen), BCL-XL (2762, Cell Signaling), Ubiquitin
(FL-76 Santa Cruz), and USP9X (1C4, Novus Biologicals). Antibodies used specifically for murine
antigens include p16 (sc-1207, Santa Cruz) and Mcl-1 (Rockland). A monoclonal antibody
(10H2F6) that specifically recognizes the β22 subunit of human Taspase1 was generated
(Promab), which was utilized for the IHC and IF assays.
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Immunoblot Analysis
Cellular lysates were collected in RIPA buffer (150 mM NaCl, 50 mM Tris-Cl, 0.1% SDS, 0.5%
Na-deoxycholate, 1% NP-40) supplemented with Complete protease inhibitor cocktail (Roche)
and separated using 10% or 12% Bis-Tris
NuPAGE gels (Invitrogen, Carlsbad, CA). Western blot images were acquired using the Fujifilm
LAS-3000 system and quantified using ImageQuant software as described (Kim et al., 2006).

Immunoprecipitation of MCL-1
U251 control- and Taspase1-knockdown cell lines were lysed in EBC lysis buffer (120mM NaCl,
50mM Tris-Cl, pH 8, 0.5% NP-40) supplemented with Complete protease inhibitor cocktail
(Roche) and 20mM N-ethylmaleimide. Lysates were incubated overnight at 4°C with 5µg MCL-1
antibody (SC-819, Santa Cruz) adsorbed to protein-A beads (GE Healthcare).

Input and

immunoprecipitated lysates were resolved on NuPAGE gels as described and blotted for MCL-1
and ubiquitin (FL-76, Santa Cruz).

Immunohistochemistry and Immunofluorescence
Paraffin-embedded primary human cancer tissue sections were obtained from the Department of
Pathology and Immunology at Washington University in Saint Louis and antigen retrieval was
performed using a pressure cooker (Biocare) and Target Retrieval Solution (Dako). A monoclonal
antibody (10H2F6) that specifically recognizes the β22 subunit of human Taspase1 was
generated (Promab), which was utilized for the IHC and IF assays. For immunohistochemistry,
glioblastoma, melanocytic nevi, and melanoma sections were stained with anti-Taspase1
monoclonal antibody (10H2F6), while melanoma and melanocytic nevi were stained with Melan A
(sc20032, Santa Cruz) to detect cells of melanocytic origin. Sections were developed using the
Vectastain Universal ABC Elite system (Vector Laboratories) and DAB+ chromogen (Dako)
according to the manufacturer’s protocol. Developed sections were counterstained with Mayer’s
hematoxylin (Sigma). For immunofluorescence, sections were stained with anti-Taspase1
monoclonal antibody (10H2F6) and an Alexa-488 conjugated goat-anti-mouse secondary
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antibody (A11029, Invitrogen).

Slides were mounted and nuclei were counterstained with

Slowfade+DAPI (Invitrogen). Indirect immunofluorescence images were acquired on an Olympus
(IX51) microscope with Spot Cam. Sections were quantitatively scored by capturing normal and
tumor tissue in the same field of view, optimally, otherwise from the same section using identical
capture settings. Pixel signal intensity was measured on acquired images using ImageJ software
(NIH). For xenograft studies, freshly-isolated tumor xenografts were fixed in Bouin’s fixative, and
7μm sections were subjected to antigen retrieval as stated above. Assessment of proliferative
index was performed by Ki-67 staining (MIB-1 clone, Dako USA), and developed using
immunoperoxdase. TUNEL staining was performed as per the manufacturer’s protocol (Roche).

Tumor Xenograft Assay
U251 glioblastoma lines transduced with control- or Taspase1-shRNA retroviruses were selected
for 3 days in 1.5μg/mL puromycin. Cells were then harvested and suspended in RPMI 1640
media in a 2:1 ratio with growth factor reduced Matrigel (BD Biosciences, San Jose, CA). Ten
million cells were engrafted into each flank of male NOD-scid IL2Rγ

-/-

mice (Jackson Lab)

between 6-8 weeks of age. Tumor size was measured with calipers and volume determined as
described previously (21). Tumor volumes were compared using a two-tailed Student’s t test. For
in vivo ABT-737 treatment, mice were injected with vehicle (30% propylene glycol and 5%
3

Tween-80 in D5W, pH 4.65) when tumors reached a volume of approximately 300-500mm .
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2.11 Figures

Figure 2.1. Taspase1 is required for the maintenance of MYC-RAS
embryonic fibroblasts (MEFs).
G12V

G12V

transformed mouse

transduced MEFs of the indicated genotypes were treated with 500 nM 4A, MYC-RAS
hydroxytamoxifen (4-OHT) for 6 hours to activate R26-creERT (a tamoxifen inducible Cre
recombinase driven by the ubiquitous Rosa-26 promoter). Deletion of the conditional (floxed; f)
5
G12V
transduced MEFs of the
Taspase1 allele was confirmed by PCR at day 3. B, 10 MYC-RAS
indicated genotypes were mock (DMSO) or 4-OHT treated for 6 hours before plating on 6 cm
dishes. Cells were photographed and counted at day 5. Data presented are mean ± SD of
4
G12V
transduced MEFs of the
duplicates of three independent experiments. C, 5x10 MYC-RAS
indicated genotypes were treated as in B and plated on soft agar. Positive clones (≥200μm) were
scored 1.5-2 weeks after the initial plating. Insets are higher-magnification images. Data
presented are mean ± SD of duplicates of two independent experiments. The average of colony
number in mock treated plates was assigned a value of 1 for comparison. Asterisk indicates p <
0.01, determined by Fisher’s exact test.
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Figure 2.2. Taspase1 is not a classical oncogene.
4

A, NIH/3T3 cells were transduced with the indicated genes and 5x10 cells were plated on soft
agar in each 6 cm dish. Positive clones (≥200μ m) were scored 10 days after the initial plating.
Insets are higher-magnification images. Data presented are mean ± SD of duplicates of two
independent experiments. T1 denotes Taspase1. B, Wild-type primary MEFs were transduced
4
with the indicated pairs of genes and 5x10 cells were plated on soft agar in each 6 cm dish.
Positive clones (≥200μm) were scored 2-3 weeks after the initial plating. Inserts are highermagnification images. Data presented are mean ± SD of triplicates of two independent
experiments.
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Figure 2.3. Taspase1 is required for the proliferation of human cancer cells.
A, Taspase1 protein expression of the indicated human cancer cell lines was assessed by antiTaspase1 α28 antibody. Western blot for β-actin indicates equal loading. The relative
expression of Taspase1 versus β-actin in hTERT-BJ-1 cells was assigned a value of 1 for
comparison. B, Human cancer cell lines with control- or Taspase1-knockdown were plated on 6well plates and cell number was assessed four days after initial plating. The average cell number
of control-shRNA cells was assigned a value of 1 for comparison. Data presented are mean ±
SD of duplicates of three independent experiments. C, Stable knockdown of Taspase1 in the
indicated human cancer cell lines was determined by anti-Taspase1 α28 immunoblot. The
expression of p16, p21, p27, Cyclin E2, and Cyclin A was determined by respective antibodies.
The β-actin immunoblots indicate equal protein loading.
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Figure 2.4. Deficiency of Taspase1 results in increased anoikis and reversion of the transformed
phenotype in SK-MEL-2 melanoma and U251 glioblastoma cells.
A, Human cancer cell lines with control- or Taspase1-knockdown were stained with annexin V
and analyzed by FACS to assess cell death. B, Human cancer cell lines with control- or
Taspase1-knockdown were cultured in PolyHEMA treated 6-well plates for 3 days, stained with
annexin V, and analyzed by FACS to assess cell death. C, SK-MEL-2 or U251 cells with controlor Taspase1-knockdown were plated on soft agar. Positive clones ≥
( 100 μm) were scored 2-3
5
weeks after the initial plating of 10 cells per 6 cm dish. Annexin V stains positive for apoptotic
cells. Data presented in A, B, and C are mean ± SD duplicates of three independent
experiments.
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Figure 2.5. Taspase1 deficiency de-stabilizes MCL-1 protein and sensitizes U251 glioblastoma
cells to cell death stimuli.
A, Cellular extracts of SK-MEL-2 or U251 cells with control- or Taspase1-knockdown were
subjected to Western blot analyses using the indicated antibodies. B, U251 cells with the
indicated knockdown were treated with various apoptotic stimuli, stained with annexin V, and
analyzed by FACS. Cellular extracts of the indicated knockdown were subjected to immunoblot
analyses using respective antibodies. Anoikis assay cells were plated in PolyHEMA coated
plates for 3 days. For chemotherapy-induced cell death, cells were treated with 100 μg/mL of
etoposide or 10 μM of doxorubicin for 30 hours. Data presented are mean ± SD of duplicates of
two independent experiments. C, U251 cells with control- or Taspase1-knockdown were mock
(DMSO) or ABT-737 treated for 24 hours, and cell death assessed by FACS analysis of annexin
V staining. Data presented are mean ± SD of triplicates of two independent experiments. D,
Transcript levels of MCL-1 in control- or Taspase1-knockdown U251 cells were determined by
quantitative RT-PCR analysis where the transcript level in control-knockdown cells was assigned
a value of 1 for comparison. E, U251 cells with control- or Taspase1-knockdown were subjected
to cyclohexamide with or without MG132 treatment for the indicated periods of time, and protein
levels of MCL-1 and β-actin were determined by immunoblot. F, Analysis of transcript levels for
known regulators of MCL-1 stability, including MULE, β-TrCP, TCTP, and USP9X. G, U251
treated with MG132 were lysed and immunoprecipitated for endogenous MCL-1. Ubiquitin
immunoblot determines MCL-1 ubiquitination state. H, USP9X levels were determined for U251
control- and Taspase1-knockdown by immunoblot. Thanks go to H. Liu for MCL-1 stability and
ubiquitination westerns, and to S. Takeda for MCL-1 qPCR.
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Figure 2.6. Taspase1 is over-expressed in human glioblastoma and is required for for U251
glioblastoma maintenance in vivo.
A, U251 cells with control- or Taspase1-knockdown were injected into the flanks of NOD-scid
-/IL2Rγ mice and tumor growth was measured every other day. * indicates p < 0.001. B,
Proliferative index of U251 xenografts was determined by Ki-67 immunohistochemistry. Sections
shown at 20X magnification. Bar graph represents mean ± SEM of Ki-67+ cells per 10X field (10
fields per tumor, n=2 tumors each). C, Cell death resulting from ABT-737 treatment was
assessed by TUNEL assay 12h after a single IP injection of vehicle control or ABT-737. Sections
shown are 10X fields of FITC-TdT (green) and DAPI (blue). Bar graph represents mean ± SEM
of TUNEL+ cells per 10X fields (10 fields per tumor, n=2 tumors each). D, Immunohistochemical
analysis of Taspase1 expression in primary human GBM and adjacent normal brain using an antiTaspase1 monoclonal antibody (10H2F6). High magnification pictures of boxed areas are
provided where the left panel is normal and the right is tumor.
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Figure 2.7. Taspase1 over-expression in NIH/3T3 and primary MEFs.
A, Western blot analysis of Taspase1 expression in NIH/3T3 cells transduced with vector control,
G12V
, and human Taspase1 (T1). B, Western blot analysis of Taspase1 expression in
RAS
primary MEFs transduced with vector control or Taspase1 in conjunction with the indicated
oncogenes.
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Figure 2.8. Taspase1 loss using two, independent sh-RNAs impedes proliferation in SK-MEL-2
and U251.
A, Western blot analysis of Taspase1 level in U251 and SK-MEL-2 cell lines transduced with
Taspase1 shRNA constructs. B, Cells with the indicated knockdown were plated on 6 well plates
and counted four days after the initial plating. Data represents the proportion of cells compared
to control knockdown where the average cell number of control knockdown cells was assigned a
value of 1. Data presented are mean ± SD of duplicates of two independent experiments.
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Figure 2.9. Cell cycle analysis of human cancer cell lines with Taspase1 deficiency
Cell cycle analyses of cancer cell lines with control- or Taspase1-knockdown by propidium iodide
(PI) staining and FACS analysis for DNA content. U251 cells were not included due to highly
variable DNA content (Pershouse et al., 1993).
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KIP1

Figure 2.10. Analysis of p27

regulation in U251 with Taspase1 deficiency.

KIP1

was determined by qRT-PCR, where U251 control knockdown was
A, Transcript level of p27
assigned a value of 1. Asterisk indicates p < 0.05. B, U251 cells with control- or Taspase1knockdown were treated with 10µg/mL cycloheximide for the indicated times and immunoblotted
KIP1
for p27 . Actin blot indicates equal loading.
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Figure 2.11. Models for the core apoptotic pathway and its interaction with Taspase1
A, Model depicts the hierarchical regulation of apoptosis. B, Model for the loss of Taspase1
expression in regulation of cell death in susceptible cancer cells.
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Figure 2.12. Analysis of SK-MEL-2 sensitivity to cell death with Taspase1 deficiency
A, SK-MEL-2 melanoma cells with control-, Taspase1-, and MCL1-knockdown were analyzed for
cell death by annexin V staining after being subjected to polyHEMA culture culture for 3 days, or
200μg/mL etoposide or 10μM doxorubicin for 30 hours. Data presented are mean ± SD of
duplicates of two independent experiments. B, SK-MEL-2 cells with control- or Taspase1knockdown were treated with DMSO (mock) or 500nM of ABT-737 for 24 hours and analyzed for
cell death by annexin V staining. Data presented are mean ± SD of triplicates of two independent
experiments. C, MCL-1 transcript level in SK-MEL-2 was determined by quantitative RT-PCR
analysis. Data presented are mean ± SD of duplicates of two independent experiments.
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Figure 2.13. MCL-1 level is not stabilized by GSK3-β inhibition in Taspase1-deficient cells
A, U251 cells with control- or Taspase1-knockdown were subjected to treatment with 4 µM TZDZ8, an inhibitor of GSK3β, for 12 hours, and protein levels were determined with the indicated
antibodies. B, U251 and MDA-MB-231 cells were treated with the indicated doses of TZDZ-8 for
12 hours and the protein levels were determined with the indicated antibodies. MCL-1 was
stabilized in MDA-MB-231 but not U251 cells upon the inhibition of GSK3-β.
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Figure 2.14. Taspase1 levels in U251 glioblastoma xenografts.
Individual tumors expressing the indicated knockdown construct were harvested from xenografted
-/NOD-scid;IL2Rγ mice at day 24 post-injection. Tumor lysates were prepared and subjected to
immunoblot analyses with the indicated antibodies.
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Figure 2.15. Examination of Taspase1 expression in human glioblastoma
Immunohistochemical analysis for Taspase1 expression in paired primary GBM and normal brain
tissues from the same group of patients (n = 13) were scored and presented as a scatter plot.
Sections were scored for the predominant (>50%) cell type based on the outlined criteria (left
panel) and the statistical significance was determined by Chi-squared test. Normal refers to
histological normal white matter. Small versus large nucleoli are defined by the diameter of
individual nucleolus ≤ 25% or >25% compared to the diameter of its respective nucleus. Asterisk
denotes p < 0.0001.
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Figure 2.16. Demonstration of the specificity of Taspase1 immunohistochemistry.
The specificity of immunohistochemical staining for Taspase1 expression in primary glioblastoma
tissues by the anti-Taspase1 primary antibody (10H2F6) was demonstrated by the loss of
staining when 50 μg/mL of the recombinant Taspase1 immunogen but not 50 μg/mL BSA (nonspecific control) was pre-incubated with the antibody before staining.

53

Figure 2.17. Examination of Taspase1 expression in melanoma.
A, Immunohistochemical analysis of Taspase1 expression in melanoma and melanocytic nevus
was performed with an anti-Taspase1 monoclonal antibody (10H2F6) (right).
Immunohistochemical stain of consecutive sections using an anti-Melan A antibody identify both
benign and malignant melanocytes as a reference (left). B, Immunofluorescence analysis of
Taspase1 expression on melanoma (left bottom panel) and melanocytic nevus (right bottom
panel) was performed with an anti-Taspase1 monoclonal antibody (10H2F6), where dotted lines
demarcate
regions
that
are
predominantly
melanocytes
from
keratinocytes.
Immunohistochemical stain of consecutive sections using an anti-Melan A antibody identify both
benign and malignant melanocytes as a reference (top two panels).
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Table 2.1. Mutation status of sequenced genes in the NCI60 cancer cell lines used in this study.
Known mutations in the cancer cell lines used in this study were retrieved from the Cancer
Genome Project (http://www.sanger.ac.uk/genetics/CGP).
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3.1 Taspase1 is an evolutionarily conserved threonine protease important in
tumorigenesis and tumor maintenance
3.2 Rational design of peptidomimetic inhibitors for Taspase1
3.3 A cell based dual-fluorescence reporter screen identifies NSC48300/TASPIN-1
as a potent inhibitor of Taspase1 in vitro and in vivo
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3.1 Taspase1

is

an

evolutionarily

conserved

threonine

protease

important

in

tumorigenesis and maintenance

Taspase1 is an evolutionarily conserved N-terminal nucleophile protease
Taspase1 is a threonine endopeptidase that is highly conserved from plants to fish, flies, and
man. Taspase1 is translated as a 50kDa proenzyme that is comprised almost entirely of an
Asparaginase_2 domain (Pfam PF01112), which is part of a larger superfamily of proteins known
as the N-terminal nucleophile (Ntn) hydrolases. As the name suggests, reactive nucleophiles of
this family reside on the N-terminus of mature Ntn hydrolases, which are typically translated as
proenzymes that require autoproteolytic activation. At the core of the Ntn hydrolase structure
resides an αββα folding motif with α helices flanking anti-parallel β sheets, which is true of
Taspase1 as well (Figure 3.1), though the crystal structure reveals significant conformational
divergence from other Asparaginase_2 proteins (Khan et al., 2005).

Other members of the Asparaginase_2 family include L-asparaginase, which catalyzes the deamidiation of asparagine to aspartic acid and aspartyl-glucosaminidase (AGA), which is involved
in the breakdown of N-linked glycoproteins, thus making Taspase1 the only protease in this
family.

Despite divergence in structural conformation and substrate specificity, autocatalytic

activation is a common feature of Ntn hydrolases, where the active nucleophile in the mature
enzyme is also thought to be the autocatalytic nucleophile (Saarela et al., 2004). The maturation
from Ntn pro-enzymes involves an initial N→ O acyl rearrangement, which reveals the catalytic
α-amino group on the threonine nucleophile. In lysosomal AGA, like Taspase1, aspartic acid
precedes the threonine nucleophile, and it is thought to provide conformational strain, promoting
activation.

Autoproteolysis of the Taspase1 pro-enzyme forms a mature α28/β22 heterodimeric enzyme
which further assembles into the active heterotetrameric enzyme (Hsieh et al., 2003a; Khan et al.,
2005).

Taspase1-mediated cleavage follows distinct aspartate residues of conserved

57

QψD/GXXD motifs (Figure 3.1).

Taspase1 was cloned as the protease responsible for the

proteolytic maturation of the human homolog of Drosophila trithorax, Mixed Lineage Leukemia
(MLL).

Since its discovery, additional Taspase1 substrates were identified, including MLL2,

TFIIAα-β (GTF2A1), ALF (TFIIAτ), and Drosophila HCF (dHCF), which are all nuclear factors,
suggesting that Taspase1 potentially modulates a broad array of biological processes (Capotosti
et al., 2007; Takeda et al., 2006b; Zhou et al., 2006). Indeed Taspase1-mediated maturation of
HCF and MLL is critical for orchestrating cell cycle progression (Julien and Herr, 2003; Takeda et
al., 2006b).

Taspase1 is required for tumor maintenance
Our prior studies demonstrated that Taspase1 is required for efficient oncogenic transformation
and is critical for maintenance of the transformed phenotype in genetically defined murine tumor
cells. Deficiency of Taspase1 decreased the proliferative capacity of a variety of human cancer
cell lines, including melanoma, glioblastoma and adenocarcinoma of the colon, ovary, lung,
prostate, and breast.

In certain cell lines, Taspase1 maintains the expression of the anti-

apoptotic BCL-2 family member MCL-1. Loss of Taspase1 in the glioblastoma cell line U251
increased its sensitivity to chemotherapies like doxorubin and etoposide, in vitro. Mechanistically,
we expected the decrease in MCL-1 level to increase the sensitivity to the selective BCL-2/BCLXL antagonist ABT-737. Indeed, Taspase1 deficiency caused U251 glioblastoma to have a lower
proliferative index, increased basal cell death, and increased sensitivity to ABT-737 treatment in
vivo. The anti-cancer effect of Taspase1 loss in cancer cell lines in vitro and in vivo, and that
Taspase1 is over-expressed in human cancers, spurred the search for Taspase1 inhibitors to
validate Taspase1 as a pharmacological target for cancer therapy (Niehof and Borlak, 2008;
Scrideli et al., 2008; Takeda et al., 2006b).
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3.2 Rational Design of peptidomimetic inhibitors of Taspase1

Structural properties of Taspase1 guide rational design of peptide inhibitors
Taspase1 has an exquisite specificity for its substrate cleavage site. MLL harbors two Taspase1
cleavage sites—cleavage site 1 and 2 (CS1 and CS2), which are separated by 53 amino acids,
where CS2 is thought to be more efficiently processed than CS1 (Hsieh et al., 2003a). Alanine
scanning mutagenesis of the MLL CS2 (KISQLD/GVDD) reveals a low tolerance for substitutions
in the cleavage site consensus. Mutations revealed that the P1 aspartate and P1’ glycine are
essential, while P2 leucine, P3 gluatmine, and P5 isoleucine are important but non-essential for
Taspase1-mediated proteolysis, whereas aspartates at position P3’ and P4’ are dispensable
(Chen, et al. in preparation). With such specificity, rational design of a Taspase1 inhibitor might
be possible, based on a short peptide specific to Taspase1 substrate MLL CS2.

Methods for assessment of Taspase1 inhibition
To assess potential inhibitors, we generated three assays and adapted them for validation of
Taspase1 inhibition, screening for further inhibitors of Taspase1, or both.

The first was

established while isolating Taspase1, employing an activity-based purification scheme which
utilized an in vitro cleavage system to chase MLL-cleavage ability in cellular fractions (Hsieh et
al., 2003a). An in vitro transcribed and translated (IVTT),

35

S methionine-labeled fragment of

human MLL1 (aa2,500-2,800) with a mutation engineered at the CS1, was employed as a CS2specific cleavage reporter (p45

MLL/CS2

). The cleavage of p45

MLL/CS2

by recombinant Taspase1

(rTaspase1) was resolved by SDS-PAGE and examined by autoradiography.

Inhibition of

Taspase1 cleavage results in the disappearance of cleaved product p33 and an increase in the
MLL/CS2

non-cleaved p45

(Figure 3.2). Though this method benefits from high specificity, it is not

practical for use as a high-throughput screening method.

The second assay is a cell-based assay developed as a method to assess the ability of potential
Taspase1 inhibitors to penetrate the plasma membrane and inhibit Taspase1 mediated cleavage
of a dual-fluorescent reporter substrate.

A 293T human embryonic kidney cell line was
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engineered to stably express a dual fluorescent Taspase1 proteolytic reporter (DFPR).

The

DFPR is constructed from a peptide similar to the in vitro cleavage assay described previously.
The DFPR reporter consists of the MLL polypeptide (aa2,400-2,900, p75

MLL

), which contains the

CS1 and CS2 Taspase1 cleavage sites and is flanked on the N-terminal by EGFP/NES (nuclear
export signal) fusion and on the C-terminal by a NLS (nuclear localization signal)/dsRED2 fusion.
Upon Taspase1-mediated cleavage, DFPR displays cytosolic green (eGFP/NES-p47) and
nuclear red fluorescence (p28-NLS/dsRED2) that can be detected by fluorescence microscopy.
Inhibition of Taspase1 results in non-cleavage of newly synthesized DFPR, exhibiting increased
yellow fluorescence upon the merge of green and red fluorescence (Figure 3.3). This method is
suitable for microscopy based high throughput screening, and though the sensitivity and
specificity of Taspase1 cleavage inhibition is less than that of the in vitro cleavage assay, this
assay readily identifies compounds which are already bioactive.

The final assay developed to assess Taspase1 inhibition is a FRET (Fluorescence Resonance
Energy Transfer)-based in vitro cleavage assay. The FRET-based Taspase1 proteolytic reporter
(FRPR, MCA-KISQLDGVDD-DNP) consists of a 10 amino acid MLL CS2 consensus sequence
conjugated with a fluorogenic coumarin (MCA) group and a 2,4-dinitrophenyl (DNP) quenching
group at its N- and C-terminus, respectively (Figure 3.4). Cleavage of the FRPR substrate can be
monitored over time using a spectrofluorometer, and the kinetics of inhibition can be determined
by varying the inhibitor concentration and performing non-linear regression on the aggregated
reaction progress curves. In this regard, this FRET-based assay was validated by establishing
that HTI-9 (ISQLAGVDD) which is an alanine mutant of the cleavage reporter acts as a
competitive inhibitor of the FRPR cleavage reaction (Figure 3.5). This assay has been adapted
for both for determination of inhibition kinetics as well as a high throughput screen, where a doseresponsive decrease in endpoint fluorescence is scored as positive for Taspase1 inhibitory
activity.
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Rational design of peptide-based Taspase1 inhibitors
The only other characterized threonine nucleophile protease in the human genome is the
proteasome, which, like Taspase1, is a member of the Ntn hydrolase superfamily. The original
proteasome inhibitors consisted of peptidyl aldehydes which inhibited the proteasome by forming
a hemi-acetal adduct with the threonine nucleophile. Based on subsequent studies revealing that
leucine is the preferred P1 position for proteasomeal cleavage, a Phe-Leu dipeptidyl boronic acid
was developed with specific sub-nanomolar inhibitory activity against the proteasome.

The

boronic acid was postulated to form stable tetrahedral intermediates with the threonine
nucleophile, while remaining much less reactive to cysteine proteases because of the weak
bonding efficiency between sulfur and boron (Adams et al., 1998). The dipeptidyl boronic acid,
known now as Velcade (bortezomib), has single agent efficacy in treatment of multiple myeloma
(MM) and non-Hodgkin’s lymphoma (NHL).

Second generation peptide-based proteasome inhibitors have been generated with epoxyketone
pharmacophores, which was a development based on the observation that a microbial anti-tumor
natural product epoxomicin had inhibitory activity at the proteasome (Sin et al., 1999). The potent
and specific inhibition of the proteasome was structurally defined by its selective binding of the
peptide sequence to the substrate binding site of the proteasome as well as the stereospecific
and irreversible interaction of the epoxyketone with the reactive threonine nucleophile (Groll et al.,
2000). Subsequent modification of a Phe-Leu-Phe-Leu tetrapetide epoxyketone generated the
proteasome inhibitor carfilzomib, which is currently under clinical trial for MM (Demo et al., 2007;
Elofsson et al., 1999).

Based on the proteasome as a precedent for rational design of effective threonine protease
inhibitors, we collaborated with M. Bogyo and colleagues at Stanford University to design,
generate, and test short peptide inhibitors for Taspase1. Additionally, the evolutionary history of
Taspase1 informs the placement of reactive pharmacophores.
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As a descendant of an

asparaginase, which cleaves the isopeptide bond on asparagines to generate aspartate,
Taspase1 may have specificity for either main chain substrates, or isopeptide substitutions.

Based on the MLL CS2, the ISQLD peptide was modified on the P1 aspartic acid residue to bear
vinyl sulfone, vinyl ketone, epoxyketone, and boronic acid pharmacophores, which are known to
be effective at inhibiting the proteasome threonine nucleophile (Figure 3.6) (Lee et al., 2009).
Using the FRET-based kinetics assay, the vinyl sulfone substitution (yzm18) on the main
backbone of the peptide inhibitor exhibited the most potent activity with an IC50 of 29μM, while the
vinyl ketone (yzm19) was less potent with an IC50 of 63μM. Interestingly, the vinyl sulfone placed
on the P1 aspartate side chain was minimally active with an IC50 > 100μM, suggesting
pharmacophores, at least the vinyl sulfone, placed on the main chain are likely to be more potent
inhibitors of Taspase1 (Figure 3.6).

Continued incubation with yzm18 did not increase the

potency of substrate cleavage inhibition, suggesting that yzm18 is not acting as a covalent,
irreversible inhibitor of Taspase1 (Figure 3.7).

Treatment of SV40-transformed murine embryonic fibroblasts (MEFs) with the ISQLD-vinyl
sulfone had minimal ability to inhibit cellular proliferation, which is a phenotype expected from
Taspase1 loss, based on our previous studies (Figure 3.8) (Takeda et al., 2006b). Whether this
is due to poor cell permeability, relatively weak ability to inhibit Taspase1, or both is a matter for
further investigation. Although the in vivo application of ISQLD-vinyl sulfone was limited, these
inhibitors represent a proof of principal of rationally designed, peptide-based Taspase1 inhibitors
and offers valuable mechanistic insights to aid the future development of more potent inhibitors.
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3.3 A cell based dual-fluorescence reporter screen identifies TASPIN-1 as a potent
inhibitor of Taspase1 in vitro and in vivo

A cell-based screen to identify small molecule inhibitors of Taspase1
To identify bioactive Taspase1 inhibitors, we employed a cell-based screen using a 293T cell line
expressing a dual fluorescence Taspase1 substrate cleavage reporter where inhibition of
Taspase1 results in the non-cleavage of the reporter and subsequent co-localization of red and
green signals, as described in section 3.2.

We screened the National Cancer institute’s

Developmental Therapeutics Program (NCI-DTP) diversity set library of 1,900 compounds and
identified 50 candidate inhibitors. A secondary screen using the in vitro cleavage assay was
performed, which confirmed five compounds as highly active Taspase1 inhibitors (Figure 3.9). To
further characterize these inhibitors, a tertiary screen was undertaken in which we employed the
well-characterized Caspase-8-mediated cleavage of the BH3-only molecule BID as a reporter
system to assess the target promiscuity of identified inhibitors.

Caspases, like Taspase1,

proteolyze substrates after the P1 aspartate of their target cleavage sequence (Zha et al., 2000)
and thus can serve as a stringent control for the specificity of any observed inhibitory activity.
Among the top five compounds exhibiting Taspase1 inhibitory activity, four have no specificity for
Taspase1 over Caspase 8 inhibition, while one compound—NSC48300—only targets Taspase1
(Figure 3.9). This establishes NSC48300, [4-[(4-arsonophenyl)methyl]phenyl] arsonic acid, as a
very specific small-molecule Taspase1 inhibitor and was thus designated as TASPIN-1.

TASPIN-1 is a non-competitive and reversible inhibitor of Taspase1
To characterize NSC48300/TASPIN-1 further, we employed the in vitro cleavage assay to
determine whether TASPIN-1 is a more potent inhibitor than our previously described peptide
vinyl sulfone (yzm18). The IC50 for TASPIN-1 is less than 10μM (Figure 3.10 A), which is less
than the IC50 of yzm18.

Like yzm18, it appears that TASPIN-1 is a reversible inhibitor of

Taspase1 as increased time of incubation with Taspase1 does not increase the inhibition of
substrate cleavage (Figure 3.10 B). Interestingly, the overall structure of TASPIN-1, including its
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hydrophobic, symmetric core specifies its inhibitory capability as free arsenic acid itself does not
inhibit Taspase1, even at high concentrations (Figure 3.10 A). In silico pharmacophore modeling
based on TASPIN-1 predicted several possible inhibitors already in the NCI chemical repository
by docking TASPIN-1 in the crystal structure for Taspase1 and assuming a tetrahedral Asp-Gly
adduct as a model. These structural probes, when tested, suggest that the arsenic acid moiety is
still important for inhibitory activity, and that substitutions on the hydrophobic core of
NSC48300/TASPIN-1 decrease the potency of inhibition (Figure 3.10).

To characterize the mechanism by which NSC48300/TASPIN-1 inhibits Taspase1, we performed
kinetic analyses using a FRET-based kinetics assay. Taspase1 incubation with the quenched
pair fluorescence probe MCA-KISQLDGVDD-DNP results in its cleavage and release of the DNP
quencher and subsequent linear accumulation in fluorescent signal over time (Figure 3.5 and
3.11). This analysis determined an apparent KM of the FRPR as 9.20 ± 2.43 µM (Figure 3.11).
Reaction progress was monitored with varying concentrations of TASPIN-1 and steady state
rates were plotted against varying reporter substrate concentrations. Non-linear regression was
performed and fitting the model from equation 1 (see Methods and Materials) revealed that
TASPIN-1 is a non-competitive inhibitor of Taspase1 with a KI of 4.22 ± 0.46 µM and α value of
1.01 (Figure 3.11, equation 2 in Methods and Materials).

TASPIN-1 treatment recapitulates the biology of the genetic loss of Taspase1
As the initial screen employed to identify TASPIN-1 specifically identifies bioactive molecules, we
assessed the molecular effects on cells treated with TASPIN-1 to determine whether TASPIN-1
could recapitulate the effects resulting from the acute, genetic deficiency of Taspase1. MYC and
G12V

RAS

ERT

cre

transformed

murine

embryonic

fibroblasts

(MEFs)

generated

from

Rosa26-

/-

;Taspase1f mice can be induced to excise the remaining allele of Taspase1 by induction of

Cre-recombinase activity by treatment with the estrogen analog 4-hydroxytamoxifen. After the
G12V

excision of and subsequent loss of Taspase1 expression, MYC-RAS

transformed MEFs

exhibit a proliferative block characterized by down-regulation of G1/S Cyclins, including Cyclin A
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and Cyclin E2, with minimal increase in the upstream cyclin dependent kinase inhibitors (CDKIs)
in contrast to that observed in the human cancer cell lines that lose Taspase1 expression by shRNA.
ERT

cre

Transformed fibroblasts that do not bear a conditional allele of Taspase1 (Rosa26+/-

;Taspase1 ) serve as a control for Cre-recombinase induction (Figure 3.12).

Concordantly, treatment of primary MEFs with TASPIN-1 caused a dose-dependent inhibition of
substrate cleavage, as assessed by disappearance of the MLL

C180

cleavage product as well as

the increase in non-cleaved TFIIAαβ and loss of the TFIIAα cleavage product (Figure 3.13). Loss
of Taspase1 substrate cleavage results in a corresponding loss of Cyclin A expression to the
level seen in Taspase1-null MEFs (Figure 3.13).

Taken together, treatment with TASPIN-1

recapitulates the Taspase1 null phenotype, suggesting that it can effectively inhibit Taspase1
function in cells. Furthermore, TASPIN-1 treatment of SV40-transformed MEFs preferentially
prohibits proliferation of Taspase1-expressing cells rather than Taspase1-null cells. As genetic
loss of Taspase1 in MEFs causes decreased proliferation, the biological effects of TASPIN-1
likely due, at least in part, to on-target Taspase1 inhibition. This is demonstrated by the restored
sensitivity of Taspase1-null MEFs to TASPIN-1 treatment when reconstituted with Taspase1
expression (Figure 3.13).

TASPIN-1 is a Taspase1-specific anti-cancer drug
Publicly available data from the NCI Developmental Therapeutics Program NCI60 cancer cell line
panel

anticancer

drug

screen

yielded

a

distinct

pattern

of

growth

inhibition

by

NSC48300/TASPIN-1 (Shoemaker, 2006). Remarkably, the sensitivity of individual cancer cell
lines to TASPIN-1 correlates well with the expression of Taspase1 within certain subtypes of
human cancer, namely breast and glioblastoma (Figure 3.14 and 3.15). Our prior analysis of the
NCI60 panel of cell lines reveals that many cancer cell lines highly express Taspase1 when
compared to the non-transformed, immortalized fibroblast cell line hTERT-BJ1 (Takeda et al.,
2006b). In agreement with our prior study, which suggests that cell lines which express higher
levels of Taspase1 are more dependent on Taspase1 for continued proliferation and survival, the
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ability of TASPIN-1 to cause growth inhibition (GI50) correlates well with the relative expression of
Taspase1 in breast cancer and glioblastoma cell lines (Figure 3.14 and 3.15).

Comparison of MCF7 and MDA-MB-231, high and low Taspase1-expressing breast cancer cell
lines, respectively, with acute loss of Taspase1 expression mediated by Taspase1 shRNA
reveals that MCF7 is more sensitive to Taspase1 loss than MDA-MB-231. Taspase1 downregulation results in a more severe proliferative defect in MCF7, as exhibited by decreased cell
count compared to control cells.

Moreover the proportion of actively proliferating cells is

decreased specifically in MCF7 with Taspase1 deficiency as determined by propidium iodide
staining (Figure 3.16). Accordingly, MDA-MB-231 is less sensitive to TASPIN-1. Similarly, U251
glioblastoma is much more sensitive to TASPIN-1 than the Taspase1-low line SF295 (Figure
3.15).

Other cancer cell lines in the NCI60 have varying degrees of correlation between

Taspase1 expression and TASPIN-1 mediated growth inhibition (data not shown).

The striking correlation between Taspase1 expression and TASPIN-1 sensitivity, taken with our
studies demonstrating that Taspase1 function is critical to tumor maintenance, suggests that
Taspase1 is the major target of TASPIN-1 in blocking cancer cell growth. Even so, due to its
chemically simple composition, TASPIN-1 likely targets more than one cellular protein or
pathway. Indeed, NSC48300 was recently shown to inhibit autotaxin, which is an extracellular
protein involved in cellular migration (Saunders et al., 2008a). Autotaxin catalyzes the conversion
of lysophoshpatidylcholine (LPC) to lysophosphatidic acid (LPA), which is a potent phospholipid
mediator of tumor and non-tumor cell motility, cellular proliferation, and tumor cell survival
(Contos et al., 2000; Hoeglund et al., 2010).

Treatment with LPA, which is downstream of

autotoxin, at levels shown to promote migration in both breast and glioblastoma cell lines (Samadi
et al., 2009; Saunders et al., 2008b) does not rescue the inhibition of growth resulting from
TASPIN-1/NSC48300 treatment (Figures 3.14 and 3.15). Therefore, the generalized anti-tumor
activity of TASPIN-1/NSC48300 is likely not to be due to the inhibition of autotaxin, rather it is
more likely due to inhibition of Taspase1.
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In vivo studies and other future directions
The general strategy for in vivo assessment of NSC48300/TASPIN-1 utilizes both xenografted
established human cancer cell lines as well as mice genetically engineered to spontaneously
develop tumors. Though the benefits of using spontaneous tumor models are clear—that they
are genetically defined tumors (with a discreet initiating event), are anatomically correct, have no
host-tumor mismatch, and have an intact immune system/tumor interface—there are multiple
benefits to using an orthotopic engraftment model. Most notably, the use of human, rather than
murine cancers, more accurately represents human tumors and consequent tumor response to
experimental therapy. Xenograft models, in general, are well-suited for pre-clinical drug studies
because of their high penetrance, synchrony, and ease of assessment, though they suffer from
the lack of stepwise genetic changes that occur in development of the tumor in the animal. This
combined with the accrual of genetic and epigenetic alterations due extended in vitro culture often
results in the cancer cell line not being able to accurately recapitulate the histology of the original
tumor (Fomchenko and Holland, 2006). Nevertheless, the degree of control offered by xenograft
models makes it a tenable system to do the initial in vivo assessment of NSC48300/TASPIN-1.

Because breast cancer cell lines respond to TASPIN-1 in a Taspase1-dependent manner, an
MMTV-Neu transgenic mouse model system was employed to gauge the efficacy of TASPIN-1 in
treating Her2/Neu driven breast tumors in vivo. In vitro, the Her2 over-expressing line BT-474
was the most sensitive of all tested breast lines to Taspase1 knockdown (Figure 3.16 B and C).
The MMTV-Neu transgene drives mammary gland specific expression of the Her2/Neu
oncogene, which results in the formation of breast tumors in female mice beginning at around 30
weeks of age. Breast cancer cell lines with ERBB2 amplifications tend to have higher expression
of Taspase1 (Figure 3.16 A).

Furthermore, Taspase1 deficient MMTV-Neu mice (MMTV-

f/f

Neu;MMTV-Cre;T1 ) are resistant to tumor formation, suggesting that Taspase1 is a critical
permissive factor for Neu-mediated breast tumorigenesis but not in MMTV-Wnt-driven tumors in a
similar system (B. A. Van Tine, unpublished data).
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Female mice with established tumors

measuring 1cm in the long dimension were initiated on a regiment of TASPIN-1 at 1, 2.5, and
5mg/kg intravenously through the lateral tail vein. There was no overt toxicity in mice, other than
an apparent injection site necrosis. Tumors initially decreased in volume, as determined by
caliper measurement, and then remained stable. Injections were discontinued when the tail vein
became hard to inject into after around four doses. At current doses and formulation, there is an
in vivo regression and cytostasis for Neu breast tumors and no change in MMTV-Wnt-driven
tumors (data not shown). Though these results are preliminary, they hold promise for TASPIN-1
as a tenable lead compound for treatment of ERBB2 over-expressing tumors, while lacking nonspecific toxicity as shown by the lack of response in MMTV-Wnt tumors. Mechanistically, it is
interesting that though Her2/Neu over-expressing breast cell lines generally have high Taspase1
expression, MCF7 appears to express Taspase1 at higher levels, suggesting that the
Her2/Taspase1 axis is particularly important in Her2/Neu dependent tumors, while in nonHer2/Neu amplified tumors have a different mechanism for Taspase1 dependence.

Glioblastoma cell lines, like the breast cancer cell lines, respond to TASPIN-1 with sensitivity that
correlates with Taspase1 expression. Since there are very few drugs available for glioblastoma
treatment, identification of new therapeutic targets and compounds to treat glioblastoma is of
great importance. To test the effect of TASPIN-1 on glioblastoma, U251 transduced with a firefly
luciferase and green fluorescent protein fusion protein (fLuc-GFP plasmid a generous gift from D.
Piwnica-Worms) retrovirus was subcutaneously engrafted into the flanks of NOD-scid/IL2Rγ
mice.

-/-

Following engraftment, mice were initiated on a 2.5mg/kg intravenous regimen of

NSC48300/TASPIN-1, administered every other day, resulting in decreased tumor growth
compared to vehicle-treated control (Figure 3.17).

To assess the ability of TASPIN-1 to kill glioblastoma in its native site, U251-Fluc/GFP was
orthotopically engrafted into the white matter of immunodeficient NOD/SCID/IL2Rg null mice
under stereotaxic guidance. Mice were initiated on a either 2.5mg/kg or 5mg/kg intravenous
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TASPIN-1 regimen, administered every other day.

Tumor growth was monitored by

bioluminescence. Whether this will result in tumor regression is still being investigated.

Gaining access to the CNS is a significant challenge for targeting therapies to disorders across
the blood-brain barrier (BBB). Roughly all large-molecule and over 98% of small molecule drugs
are excluded by the BBB. Though it is difficult to predict which specific small molecule will cross
the BBB, there are a few characteristics associated with drugs known to cross the BBB, including
a molecular mass (less than 400-500 Da) and formation of 10 or fewer hydrogen bonds with
water. Increases in mass (and hence, surface area) are strongly correlated with exclusion from
the BBB, and increased lipid solubility has little effect on permeation of the BBB when the surface
area is higher (Pardridge, 2005).

Arsenic-containing molecules have been described to cross the blood brain barrier. Arsenic
trioxide (As2O3), used to treat relapsed acute promyelocytic leukemia (APL), has been shown to
cross the blood brain barrier in the treatment of CNS relapse of APL (Au et al., 2006). Although
this is the case, there are significant differences between arsenic trioxide and TASPIN-1. The
physical properties of NSC48300/TASPIN-1, with a molecular weight of 416 g/mol, hydrophobic
core, and 10 total hydrogen bond donor/acceptors, place it near the limits of compounds that are
known to permeate the BBB. Common solvents like dimethylsulfoxide (DMSO) and non-ionic
surfactants like Tween 80 can facilitate passage through the BBB (Azmin et al., 1985; Broadwell
et al., 1982).

Though TASPIN-1 delivery in this vehicle may increase the likelihood of a

therapeutic dose in the CNS, increased or repeated dose of intravenous TASPIN-1 did not inhibit
tumor growth in initial studies.

Whether TASPIN-1 gains access to the CNS in meaningful

quantities remains to be addressed through further testing, which involves repeated sampling the
CSF and either mass spectroscopy, HPLC, or other method to monitor the accumulation and
clearance of TASPIN-1.
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It is important to note that aside from the injection site necrosis, there was no overt toxicity
observed in mice treated with repeated doses of TASPIN-1—they maintained normal activity,
body weight, and blood count.

Studies are underway to determine the pharmacokinetics of

TASPIN-1 as well as changes in serum values in the basic metabolic panel (BMP).
deletion of Taspase1 in Mx1-cre;Taspase1

f/-

Acute

in adult mice is well tolerated in both male and

female mice over the long term (>16 weeks after cre recombinase induction, A. Searleman,
unpublished data). Though Taspase1 is critical for murine embryonic development, it appears to
be largely dispensable to normal health in adult mice.

Concordant with the classification of

Taspase1 as a non-oncogene addiction protease, it seems that certain biological circumstances,
like cancer, exhibit increased reliance on Taspase1 function and hence are exquisitely sensitive
to Taspase1 loss.

This idea hearkens back to the original description of HSF1 as a non-

oncogene addiction factor in which HSF1 deficient mice were overtly normal and only exhibited
pathology in situations of increased reliance on normal HSF1 function, like in situations of
proteotoxic stress, yet were resistant to tumor formation (Dai et al., 2007a; Solimini et al., 2007).
The defining feature—the relative of insensitivity of normal tissues compared to the sensitivity of
tumors—of non-oncogene addiction factors results in a therapeutic window which makes
inhibition of the non-oncogene addiction protease Taspase1 a promising new development in
cancer therapy.

The identification of NSC48300/TASPIN-1 as a specific inhibitor of Taspase1 is of potential
clinical significance. We previously described the critical importance of Taspase1 in maintenance
of tumor proliferation and survival, and we further demonstrate that TASPIN-1 treatment can
inhibit cancer cell proliferation in vitro and in vivo. Although presence of arsonic acid may limit
the clinical application of this particular compound because of potential non-specific toxicity,
structural determination of the Taspase1-TASPIN-1 complex would assist the future development
of Taspase1 inhibitors for cancer therapy.
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3.4 FRET-based screening reveals further leads for Taspase1 inhibitors

The tyrphostin family of tyrosine kinase inhibitors inhibit Taspase1
In collaboration with the NCI DTP, we screened the Library of Pharmacologically Active
Compounds (LOPAC 1280), which consists of 1,280 compounds that have described
pharamacological actions, including kinase inhibitors, inducers of cellular stress, and antibiotics
among others. Adaptation of the FRET-based kinetics assay as an endpoint assay converts the
detailed kinetics assay into a useful method for high throughput screening method to identify
inhibitors of in vitro Taspase1 proteolysis of the FRPR substrate. Dose-dependent decrease in
fluorescence endpoint reading is scored as a positive hit for Taspase1 inhibition, which we
subsequently validate using the radiographic in vitro cleavage assay. Interestingly, the tyrphostin
family of tyrosine phosphorylation inhibitors had multiple members that were able to inhibit
Taspase1 to different degrees (Figure 3.18).

The tyrphostin family of inhibitors appears to

irreversibly inhibit Taspase1 as inhibition of Taspsae1-mediated proteolysis of the radiographic
MLL reporter increased with longer pretreatment times of Taspase1 with the tyrphostin (Y. Lee
unpublished data). Though Tyrphostin AG538 appears to be a more potent inhibitor of Taspase1
than TASPIN-1, it may suffer from off-target effects, as it is known to be a potent inhibitor of IGFR
(Blum et al., 2000). As such, the application of tyrphostins as clinical inhibitors of Taspase1
requires further investigation.
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3.5 Methods and materials

Radiographic in vitro cleavage assay
To assess Taspase1 cleavage in vitro, an MLL cleavage reporter with a cleavage site 1 (CS1)
mutation was generated, representing aa 2500-2800 of MLL1. Mutation of CS1 by substitution of
Asp-Gly with Ala-Ala at aa 2666 results in non-cleavage at CS1 but retention of CS2, generating
two fragments p33 and p12 from the p45 non-cleaved substrate. The MLL cleavage reporter was
transcribed and translated in vitro in the presenence of

35

S-methionine using the TNT rabbit

reticulocyte lysate system according to the manufacturer’s protocol (Promega, Madison, WI).
Cleavage assays were performed in a total volume of 25 microliters with cleavage buffer (20mM
HEPES, pH 7.9, 5mM MgCl2, 20mM KCl, 10% sucrose, and 2mM DTT) with 15ng recombinant
Taspase1 pre-incubated with DMSO or appropriate amount of yzm peptide derivative (10, 100,
500μM) for 30 minutes at 30˚C before addition of 0.1 microliters of MLL reporter substrate for an
additional 30 minutes at 30̊C. Reactions were resolved on 10% Bis-Tris NuPage gels in MES
buffer (Invitrogen, Carlsbad, CA). Gels were fixed in 25% isopropanol/10% acetic acid for 30
minutes followed by signal amplification for 30 minutes using Amplify solution (G.E. Healthcare
Life Sciences, Piscataway, NJ). Gels were dried at 80˚C for 1h and exposed to BioMax MR film
(Kodak).

FRET-based kinetics assay
A quenched fluorescent probe for Taspase1 activity (FRPR) was generated by conjugating the Nterminus with a 7-methoxycoumarin-4-acetyl (MCA) fluorophore and a dinitrophenyl (DNP)
quencher at the C-terminus of the sequence Lys-Ile-Ser-Gln-Leu-Asp-Gly-Val-Asp-Asp, which
represents the cleavage site 2 (CS2) sequence of MLL1 (Tufts University Core Facility, Boston,
MA). Reactions were conducted in reaction buffer (100mM HEPES, pH 7.9, 10% sucrose, 1mM
DTT) in the presence of TASPIN-1 or vehicle control (DMSO). For inhibition studies, recombinant
Taspase1 was pre-incubated with TASPIN-1 for 30 minutes at room temperature before initiation
of the reaction by addition of FRPR to a final concentration 15μM FRPR and 100nM Taspase1,
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respectively.

Taspase1 activity was monitored by recording the accumulation of emitted

fluorescence signal (λexcitation = 328nm, slit = 10nm and λemission = 393nm, slit = 10nm) over time
using an LS55 fluorescence spectrometer with a 96-well plate adapter (Perkin Elmer, Inc.,
Waltham, MA). Steady state rates were determined for each reaction and KM, KI, and IC50 values
were determined using Prism software (GraphPad Software, Inc., La Jolla, CA), assuming
Michaelis-Menten kinetics (Khan, et al. Structure 2005).

The following equations model the

mechanism of inhibition, where α<<1 fits un-competitive inhibition, α=1 is fits non-competitive
inhibition, and α>>1 fits competitive inhibition (Saunders et al., 2008b).

𝑘𝑐𝑎𝑡 [𝑆]
𝑣
=
[𝐸]𝑡𝑜𝑡 𝐾𝑀 + [𝑆]

Equation 1: Briggs Haldane equation

𝑣
=
[𝐸]𝑡𝑜𝑡

𝑘𝑐𝑎𝑡 [𝑆]
[𝐼]
[𝐼]
�
𝐾𝑆 �1 + � + [𝑆] �1 +
𝐾𝐼
𝛼𝐾𝐼

Equation 2: General Equation for inhibition

Cell viability assay
Wild type and Taspase1-null SV40-transformed MEFs were cultured in IMDM supplemented with
10% FBS, 100U/mL penicillin/streptomycin, 2mM L-glutamine, 1mM sodium pyruvate, and 1mM
non-essential amino acids (Invitrogen, Carlsbad, CA). Five thousand cells per well were plated
16h before drug treatment in 96-well plates. After 48h of drug treatment, an MTT cell viability
assay was performed as recommended by the manufacturer (Roche, Indianapolis, IN).

Cell

viability was expressed as a fraction of control (DMSO) treated cells.

Xenograft assay
A reporter cell line was generated from the glioblastoma cell line U251 by transduction with an
amphotropic retrovirus encoding both GFP and firefly luciferase.

Cells were harvested and

resuspended in 1:2 suspension of growth factor-depleted matrigel and RPMI and one million cells
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were engrafted subcutaneously in each flank of male NOD-scid IL2Rγ mice between 6-8 weeks
-/-

of age. Tumors were engrafted on day 0 and treated with an IV preparation of NSC48300 at
2.5mg/kg every other day starting at day 1. Tumor growth was monitored by bioluminescence
imaging using an IVIS 100 system.
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3.6 Figures

Figure 3.1. Structural characteristics of Taspase1 and its substrates.
A, Ribbon diagram of the Taspase1 active heterotetramer crystal structure (PDB 2A8I) in an
orientation where the major features are visible. The N-terminal catalytic threonine (T234) is en
face on the green protomer, while the α/β/β/α structure is clearly visible in the blue protomer,
though its threonine nucleophile is facing into the page. B, Cleavage site consensus alignment of
known mammalian Taspase1 substrates reveals significant conservation of the cleavage site
residues (ClustalW2, http://www.ebi.ac.uk/Tools/clustalw2). Clevage occurs after the aspartate

in QVDG.
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Figure 3.2. Assessing Taspase1 inhibition I—the in vitro cleavage assay.
An in vitro transcribed and translated (IVTT) fragment of MLL was synthesized using a rabbit
35
reticulocyte lysate system, in the presence of S-methionine so that newly synthesized proteins
could be detected by autoradiography. This fragment of MLL, from aa 2500 to 2800,
encompasses the endogenous cleavage sequences CS1 and CS2, where CS1 is mutated by
site-directed mutagenesis, leaving only CS2. Upon introduction of recombinant Taspase1
MLL
reporter is cleaved at CS2, which is detected by autoradiography. Inhibition
(rTaspase1), p45
MLL
non-cleaved band, and decrease in the
of cleavage results in the accumulation of the p45
MLL
product.
cleaved p33
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Figure 3.3. Assessing Taspase1 inhibition II—the cell-based screening assay.
The dual fluorescence proteolysis reporter (DFPR) consists of a fragment of MLL1 between
aa2400 – 2900, which includes both endogenous Taspase1 cleavage sites (CS1 and CS2). The
N-terminus is fused to GFP and a nuclear export signal (NES), while the C-terminus is fused to
dsRED2 and a nuclear localization signal. When stably expressed in healthy 293T cells, the Cterminal/red fragment can be clearly discerned from the N-terminal/green reporter fragment by
their color and localization. Inhibition of Taspase1 to levels that substantially prevent proteolysis
of the reporter causes mislocalization of both GFP- and dsRED2-tagged fragments,
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Figure 3.4. Assessing Taspase1 inhibition III—the FRET based kinetics assay.
The reporter FRPR is a short peptide representing the MLL1 CS2. The N-terminus is conjugated
to a methoxycoumaryl fluorphore (MCA), while the C-terminus is conjugated to a dinitrophenyl
quenching group (DNP). In its native state, incident excitatory light at λex=328nm does not
produce an emission signal at λem=393nm . When stably expressed in healthy 293T cells, the Cterminal/red fragment can be clearly discerned from the N-terminal/green reporter fragment by
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Figure 3.5. HTI-9 is a competitive inhibitor of Taspase1 and cooperates with non-competitive
inhibitor NSC48300/TASPIN-1.
A, HTI-9 peptide inhibitor was determined to be a competitive inhibitor of Taspase1 using the
modified version of the Briggs-Haldane equation (equation 3.2, methods and materials), where
competitive inhibition has an α>>1. HTI-9 is a relativey weak inhibitor of Taspase1, with a Ki =
228±31μM. B, Non-competitive inhibitor NSC48300/TASPIN-1 cooperates with HTI-9 to inhibit
Taspase1 cleavage of the FRPR reporter. Shown here is the reaction progress plot.
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Figure 3.6. Proof of principle in rational design of peptide inhibitors of Taspase1.
A, Short peptide Taspase1 inhibitors are based on the cleavage site (CS2) sequence of MLL1 to
engender specificity, for engagement of Taspase1 with various pharmacophores, including vinyl
sulfones (yzm16, yzm18), vinyl ketone (yzm19), boronic acid (yzm49), and epoxyketone (yzm38).
Norleucine (yzm22) is a control peptide. These inhibitors were generated in collaboration with M.
Bogyo and colleagues at Stanford University. B, In vitro cleavage assay demonstrates inhibition
MLL
reporter substrate with increasing doses of peptide inhibitor
of Taspase1 cleavage of the p45
(10, 100, and 500μM).
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Figure 3.7. The vinyl sulfone yzm18 is a reversible inhibitor of Taspase1.
A, Reversibility was determined by pre-incubation with yzm18 and Taspase1 with increasing time
MLL
substrate. Irreversible inhibition is marked
(15, 30, and 60 minutes) before introducing the p45
by decreased ability to process substrate with longer pre-incubation times. B, Band intensities for
the radiographic cleavage assay were quantified using the STORM phosphorimaging system.
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Figure 3.8. The vinyl sulfone yzm18 is not a potent inhibitor of Taspase1 in vivo.
The effect of yzm18 in vivo was assessed by incubation of with SV40-transformed wild type
Taspase1 MEFs over 3 days before performing an MTT assay to assess viable cell mass. Low
concentration (0.1μM) yzm18 treated cells were assigned a value of 1.
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Figure 3.9. An in vitro screen identifies NSC48300/TASPIN-1 as a potent bioactive inhibitor of
Taspase1.
293T cells expressing DFPR were plated in 96-well plates the day before treatment with the NCI
Diversity Set of 1900 compounds. Hits were validated by the in vitro cleavage assay and
subsequently evaluated for Taspase1 inhibition specificity using rCaspase8 (cysteine aspartase)
and its proteolytic target Bid, Of 1900 compounds, only NSC48300/TASPIN-1 was a bioactive
and specific inhibitor of Taspase1. Thanks goes to S. Takeda for contributing work to this screen.

83

Figure 3.10. Structural features of TASPIN-1 define its Taspase1 inhibitory activity.
A, TASPIN-1 is a potent inhibitor of in vitro Taspase1 reporter cleavage, with an IC50 ~ 5μM. B,
To determine if TASPIN-1 is a reversible or irreversible inhibitor of Taspase1, TASPIN-1 was preMLL
incubated with Taspase1 for the indicated times before addition of radiolabeled p45 . C,
Pharmacophore modeling identifies putative Taspase1 inhibitors based on the TASPIN-1
MLL
was used to test the efficacy of inhibition. Thanks
pharmacophore. In vitro cleavage of p45
goes to Y. Lee for contributing this figure.
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Figure 3.11. NSC48300/TASPIN-1 is a non-competitive inhibitor of Taspase1.
A, Non-linear regression of reaction progress curves of the FRET-based kinetics assay with
TASPIN-1 treatment revealed that Taspase1 is non-competitive inhibitor of Taspase1 (α=1.01,
equation 2 in the Methods and materials section) with a Ki of 4.24 ± 0.46μM. B, Lineweaver-Burk
plot indicates that unlike Vmax, KM does not vary with Taspin-1 concentration, consistent with noncompetitive inhibition.
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Figure 3.12. Molecular consequences of genetic loss of Taspase1.
G12V

transformed primary MEFs bearing a conditional allele of Taspase1 (R26MYC/RAS
ERT
f/ERT
+/+
cre ;T1 ) or control (R26-cre ;T1 ) were subjected to a 6h pulse of 500nM of 4-OH
tamoxifent to induce Cre-recombinase activity. Lysates were generated 48h after treatment and
immunoblotted with the indicated antibodies.
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Figure 3.13. TASPIN-1 treatment recapitulates the Taspase1-null phenotype.
A, Primary Taspase1 wild type or null MEFs were subjected to treatment with the indicated
concentration of TASPIN-1. Lysates were generated 24h after treatment and immunoblotted with
the indicated antibodies. B, Taspase1 null SV40-transformed fibroblasts were reconstituted with
various amounts of hTaspase1 by retroviral transduction and subjected to treatment with
TASPIN-1. Viable cell mass was determined by MTT assay. Lysates were generated form wildtype, Taspase1-null, and Taspase1 reconstituted SV40-transformed MEFs and subjected to
Taspase1 immunoblot and actin immunoblot to demonstrate equal loading
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Figure 3.14. TASPIN-1 sensitivity is correlated with relative Taspase1 expression level in breast
cancer cell lines.

A, Comparison of normalized Taspase1 protein expression with the GI50 concentration of
TASPIN-1 demonstrated that the sensitivity of growth inhibition to TASPIN-1 correlates well with
the protein expression of Taspase1 breast cancer cell lines. Protein expression data of Taspase1
in NCI60 cell lines has been described (Takeda et al., 2006b), while GI50 data is obtained from
the NCI DTP website (http://dtp.nci.nih.gov). The protein expression and the GI50 is compared to
the mean of all five breast cancer cell lines and presented as a fraction of the standard deviation.
GI50 denotes growth inhibition 50%. B, To exclude effects of autotoxin inhibition, breast cancer
cell lines were treated with 100nM LPA or mock treated in addition to TASPIN-1 treatment. MTT
assay was performed after two days of treatment to determine viable cell mass.
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Figure 3.15. TASPIN-1 sensitivity is correlated with relative Taspase1 expression level in brain
cancer cell lines.

A, Comparison of normalized Taspase1 protein expression with the GI50 concentration of
TASPIN-1 demonstrated that the sensitivity of growth inhibition to TASPIN-1 correlates well with
the protein expression of Taspase1 central nervous system (CNS) cancer cell lines. Protein
expression data of Taspase1 in NCI60 cell lines has been described (Takeda et al., 2006b), while
GI50 data is obtained from the NCI DTP website (http://dtp.nci.nih.gov). The protein expression
and the GI50 is compared to the mean of all five brain cancer cell lines and presented as a fraction
of the standard deviation. GI50 denotes growth inhibition 50%. B, To exclude effects of autotoxin
inhibition, brain cancer cell lines were treated with 100nM LPA or mock treated in addition to
TASPIN-1 treatment. MTT assay was performed after two days of treatment to determine viable
cell mass.
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Figure 3.16. Breast cancer cell lines expressing higher Taspase1 are more sensitive to
Taspase1 loss.

A, Comparison of HER2 positive cell lines with HER2 negative lines by Western blot. Lysates
were subjected to immunoblot for HER2, Taspase1, and actin blot for comparison. B, Taspase15
shRNA transduced cells were plated at 10 cells per well in 6-well plates and counted 4 days after
plating. Control-shRNA cell count average was assigned the value 1 for comparison. C,
Proliferative status for cell lines expressing Taspase1- or control-shRNA was determined by PI
staining for DNA content and subsequent FACS analysis.
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Figure 3.17. Glioblastoma xenografts respond to TASPIN-1 treatment in vivo.
To gauge the effect of Taspase1 inhibition in vivo, a U251 glioblastoma cell line expressing a
firefly luciferase and GFP fusion protein was injected subcutaneously into the flanks of NOD-scid
-/IL2Rγ mice (day 0) and treated with an IV preparation of NSC48300/TASPIN-1 at 2.5mg/kg
every other day starting at day 1. Tumor growth was monitored by bioluminescence imaging.
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Figure 3.18. Tyrphostins are potent inhibitors of Taspase1 in vitro.
Library of pharmacologically active compounds (LOPAC 1280) screening from the FRET-based
assay identified a family of receptor tyrosine kinase inhibitors that potently inhibit Taspase1. The
table is a comparison of Taspase1 inhibition in a FRET-based determination of IC50.
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Chapter 4
Therapeutic implications of Taspase1 non-oncogene
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Taspase1 inhibition
4.4 Figures
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4.1 Future directions: in vitro studies

Balancing proliferation and apoptosis
This body of work represents the first establishment of a role for Taspase1, a non-oncogene
protease, in tumor maintenance. Because the nature of non-oncogene addiction factors is, by
definition, insufficient to drive tumorigenesis by itself, it is particularly challenging to define what
functions are critical to the ability of such factors to mediate efficient tumorigenesis. It is clear,
though, that Taspase1 is required for oncogenic transformation and maintenance of tumor
phenotypes. Taspase1 deficiency in non-transformed, primary murine fibroblasts first established
the role of Taspase1-mediated proteolysis of MLL in the orchestration of cell cycle progression
through its obligate role in driving the expression of key Cyclins E, A, and B (Takeda et al.,
2006b).

In certain tumor types like glioblastoma, in contrast with non-transformed MEFs,

Taspase1 also regulates cellular survival.

We establish that Taspase1 regulates the

deubiquitinase (DUB) protein USP9X, which was recently described as a critical regulator of the
protein stability of the anti-apoptotic BCL-2 family member MCL-1 (Schwickart et al., 2010).
Taspase1 deficiency decreased proliferation in cancer cell lines in which Taspase1 is normally
highly expressed, though unlike in MEFs, Cyclin E and A expression remain unchanged. Rather,
KIP1

the CDKI p27

was up-regulated with acute Taspase1 deficiency, which is consistent with the

G1/S phase cell cycle block observed with Taspase1 loss in cancer cell lines.

Pleiotropic regulation of proliferation and death is commonly observed in oncogenic signaling, as
well-established by the role of the transcription factor MYC in regulating both. Interestingly, all of
the described substrates for Taspase1 are nuclear factors involved broadly in regulating
transcriptional programs, giving us some insight into how a single protease might sufficiently
regulate both proliferative and apoptotic programs, and, as will likely be demonstrated later, many
other important biological programs.
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Taspase1 and the regulation of Cyclin-dependent kinase inhibitors p16

INK4A

CIP1

, p21

KIP1

, and p27

Though Taspase1 regulates both Cyclins and the upstream Cyclin-dependent kinase inhibitors
(CKDIs), it is unclear whether the cleavage of MLL has a role in modulating CDKI expression.
Direct binding of MLL, through E2F transcription factors, at Cyclin promoters has been
demonstrated, resulting in increased histone H3 lysine 4 (H3K4) trimethylation, which is an
epigenetic mark associated with positive transcriptional activity.

Taspase1 loss results in

hypomorphic H3K4 methyltransferase activity and decreased H3K4 methylation at the Cyclin E
INK4A

promoter. Yet, MLL targeting to the p16

locus is increased in Taspase1 deficiency and the

H3K4 methylation remains unchanged (Takeda et al., 2006b).

It seems counterintuitive that though MLL non-cleavage is associated with hypomorphic
INK4A

transactivation capabilities, loss of Taspase1 causes an increase in p16
Regulation of p16

INK4A

transcript.

is primarily through transcriptional control, and many possibilities exist for

why we observe p16 transcript and protein up-regulation with Taspase1 deficiency. First, it is
possible that increased targeting of non-cleaved MLL to the p16

INK4A

promoter simply displaces its

functional antagonist BMI-1, which is an oncogene known to repress p16

INK4A

transcription

(Jacobs et al., 1999). The MLL N-terminal repression domain has been shown to interact with
BMI-1 (Xia et al., 2003), which brings up the interesting possibilities that non-cleaved MLL may
displace BMI-1, lose interaction with BMI-1 (and hence MLL may become hypo-functional in its
gene-repressive activity rather than gaining a trans-activating property), or cause an allosteric
inactivation of BMI-1. A simple approach to addressing the role of BMI-1 in regulating the INK4A
locus in the absence of Taspase1 would be to assess whether the occupancy of the p16

INK4A

promoter by BMI-1 is changed. Alternatively, non-cleaved MLL could bind a different set of cofactors than cleaved MLL, rendering either enhanced trans-activation capability or loss of
transcriptional repression in a BMI-1 independent manner. For instance, MLL has been shown to
interact with the DDB1/CUL4A ubiquitin ligase machinery, which is required for RAS-induced
INK4A

p16

induction, though the biochemical mechanism explaining this induction remains unknown
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(Kotake et al., 2009). Finally, it is also possible that substrates other than MLL, like TFIIA or ALF
regulate the expression of p16

INK4A

.

Transcript levels of another CDKI, p21

CIP1

are elevated in Taspase1-null MEFs, which is likely

dependent on the activation of a canonical p53-dependent pathway. TP53 is frequently mutated
in cancer cell lines, and shRNA-induced Taspase1 loss increases p21 expression an appreciable
amount only in the lung adenocarcinoma line, A549, which is the singular cell line in the tested
panel that harbors wild type TP53. Whether Taspase1 regulates the p53 pathway is a matter for
further study.

KIP1

Perhaps the most important Taspase1-regulated CDKI is p27
CIP1

to p21

, the cyclin dependent kinase inhibitor p27

KIP1

. Sharing significant homology

potently inhibits Cyclin D1-cdk4 and

Cyclin E-cdk2 complexes at the G1/S cell cycle phase boundary. A distinguishing feature of
KIP1

p27

, however, is that its expression responds to mitogenic stimuli, as its levels are kept high in

quiescent cells, but drop rapidly upon mitogen stimulation. Translational and post-translational
mechanisms are implicated in p27 regulation, including negative feedback by Cyclin E/cdk2
phosphorylation and subsequent inactivation by proteasomal degradation (Sherr, 1996). Protein
expression of p27

KIP1

is regulated post-translationally by the ubiquitin-proteasome pathway and

depends on the action of the E3-ubiquitin ligase SKP2, which recognizes the phosphorylated
state of p27

KIP1

conferred by Cyclin E/cdk-2 (Carrano et al., 1999; Pagano et al., 1995). The

transcription factors of the forkhead family, including AFX (MLLT7/FOXO4), FKHR (FOXOA1),
and FKHR-L1 (FOXO3A) regulate p27

KIP1

transcript through RAS/PI3K (Dijkers et al., 2000;

Medema et al., 2000). Further integration with growth factor pathways occurs through the direct
phosphorylation at T157 of p27 by AKT, which causes the retention of p27 in the cytoplasm and
titrating it away from its target Cyclins, thereby preventing G1 arrest (Liang et al., 2002; Shin et
al., 2002; Viglietto et al., 2002). Recently, other oncogenic kinases such as Src, Lyn, and BCRABL, have been implicated in the direct phosphorylation of p27 tyrosine residues to regulate its
stability as well as impairing its ability to effectively inhibit the Cyclin E-cdk2 kinase (Chu et al.,
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2007; Grimmler et al., 2007), which suggests that p27 inactivation is an important task that
oncogenes must accomplish in the process of transformation.

Taspase1 down-regulation in cancer cell lines that express high basal levels of Taspase1
KIP1

uniformly up-regulate p27

. Transcript levels in U251 glioblastoma cells are up-regulated by

roughly 1.5 fold, while protein is concomitantly stabilized. These two features are reminiscent of
AFX over-expression in MEFs (Medema et al., 2000). It is therefore possible that Taspase1
regulates p27

KIP1

expression indirectly through forkhead transcription factors.

Forkhead

transcription factors, like FOXO3A, are regulated in part by growth factor signaling through the
PI3K/AKT pathway by phosphorylation and cytoplasmic retention (Brunet et al., 1999).
Preliminary evidence suggests that Taspase1 may regulate p27 in a PI3K dependent manner.
Glioblastoma cell line U251 treated with U0126 (MEK/ERK inhibitor) or LY294002 (PI3K inhibitor)
up-regulate p27

KIP1

.

In Taspase1 deficiency, which causes an up-regulation of p27 level

compared to the control, further increase in p27

KIP1

is seen only with MEK inhibition and not PI3K

inhibition, suggesting that Taspase1 is not downstream of MEK in p27 regulation, but may be
downstream of PI3K (data not shown).

Alternatively, because Taspase1 is involved in the

processing of multiple transcription factors, it is possible that Taspase1 may involve other factors
important in p27 degradation, including E3 ligases SKP2 and KPC (Carrano et al., 1999; Hara et
al., 2005; Kotoshiba et al., 2005).

Taspase1 and the regulation of the anti-apoptotic BCL-2 family member MCL-1
In primary cells, Taspase1 does not appear to regulate cell death, even upon application of death
stimuli, and Western blotting reveals that MCL-1 does not depend on Taspase1 expression
(Figure 4.3). It is only in cancer cell lines in which we see MCL-1 regulation, and even then this
phenomenon was only observed in a specific subset of cell lines.

In U251 and SK-MEL-2

glioblastoma and melanoma cell lines, respectively, Taspase1 deficiency causes a significant
destabilization of MCL-1 protein. However, among the other cell lines tested, only the A549 lung
adenocarcinoma line exhibits appreciable MCL-1 down-regulation, and even then, the down-
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regulation is modest (data not shown). Though Taspase1 is down-regulated with high efficiency
with sh-RNA targeting, there is still residual Taspase1 protein as assessed by Western blot, and
transcript levels persist at roughly 20% of control (data not shown). Taspase1 is a highly efficient
enzyme, though it seems to more efficiently process certain substrates over others, as Taspase1
sh-RNA can deplete Taspase1 expression enough to fully inhibit TFIIAαβ cleavage, but only
partially inhibit MLL cleavage. Since genetic studies in mice demonstrate that Taspase1 is the
obligate protease for MLL and TFIIAαβ cleavage, it is likely that some Taspase1-deficiency
phenotypes like MCL-1 regulation may be masked by insufficient inhibition of Taspase1 function
by this particular strategy.

We identified USP9X, a deubiquitinase that is known to stabilize MCL-1, as a Taspase1-regulated
gene. There are approximately 100 enzymes in the DUB family which play diverse roles in
cancer progression, from stabilizing receptor tyrosine kinases like EGFR and MET, to regulation
of the MDM2/p53 pathway, and the regulation of NF-κB signaling (Lopez-Otin and Hunter, 2010).
USP9X is located on the X-chromosome and is known to deubiquitinate Survivin, regulating its
association with centromeres, and hence chromosome alignment and segregation, without
affecting its protein degradation (Vong et al., 2005). Recently, USP9X was described to remove
ubiquitin from MCL-1, stabilizing the protein. Suppression of USP9X by sh-RNA knockdown
resulted in the destabilization of MCL-1 protein in multiple myeloma cells, in which overexpression of MCL-1 is a poor prognostic factor (Schwickart et al., 2010). Decreased levels of
MCL-1 resulting from USP9X deficiency increased cancer cell susceptibility to ABT-737, which
inactivates BCL-2 and BCL-XL, but not MCL-1.

We demonstrated that Taspase1-deficient

glioblastomas have impaired transcription of USP9X, enriched levels of ubiquitinylated MCL-1,
and consequent increase in sensitivity to ABT-737 in vitro and in vivo. Importantly, Dixit and
colleagues noted that increased USP9X transcript correlated with increased protein in diffuse
large B-cell lymphoma (DLBCL) cell lines, suggesting that USP9X protein expression is controlled
at the transcriptional level (Schwickart et al., 2010), just as we demonstrated in the context of
Taspase1 deficiency.
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It is interesting to note that U251 and SK-MEL-2 lose MCL-1 expression to a much higher degree
than A549 with Taspase1-loss, while in other cancer cell lines MCL-1 levels remain rather
unperturbed.

To gain clues about the mechanistic details of Taspase1-mediated MCL-1

regulation, multiple questions must be addressed. The first piece of information to be acquired,
however, is the USP9X expression level of each cell line upon Taspase1 knockdown.

One

possibility is that the Taspase1/USP9X axis is disrupted in resistant cell lines. Additionally, we
have ruled out many of the other known mechanisms by which MCL-1 stability is regulated, since
Taspase1 knockdown in U251 did not respond to GSK-3β inhibition, did not down-regulate
described E3-ubiquitin ligases MULE or β-TRCP, nor did it down-regulate the stabilizing
chaperone TCTP. A remaining possibility is that ERK-mediated phosphorylation of the MCL-1
PEST domain may dictate Taspase1-mediated control of MCL-1 stability (Domina et al., 2004).
Because Taspase1 regulates transcription factors, USP9X expression may be modulated by one
of the described Taspase1 substrates, including MLL1, MLL2, TFIIA, or ALF.

The U251 and SK-MEL-2 cell lines also differ from the other cell lines in the panel by their
embryonic origin. Glioblastoma mulitforme is thought to be of astrocytic origin and melanomas
from benign melanocytes. Both of these cell lineages are derived from the neuroectoderm, while
in contrast, the epithelium of colon, breast, lung, and prostate arise from the endoderm. MEFs,
on the other hand, are derived from the mesoderm. Historical cancer classification has relied on
this inherent and readily observable phenomenon, which provides the basis for categorization on
particular differentiation states (classification of leukemias), tissue lineage (cancers of different
tissue origins), embryonic germ layer (ectoderm-, mesoderm-, and endoderm-derived), and
histological lineage (squamous carcinoma compared to adenocarcinoma) (Garraway and Sellers,
2006). Thus, the implication is that the developmental history of a cell determines the particular
molecular constitution, whether by genetic or epigenetic means, from which tumors are formed
and by which tumors can be dismantled. In point of fact, there are no mutations in common that
distinguish SKMEL2 and U251 from the other cancer cell lines examined (Table 2.1); however,
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deregulated cellular programs arising from mutations, whether characterized or awaiting
characterization in these cell lines, perhaps interact in a unique fashion with the distinct
developmental makeup of the cell. This, in turn, may dictate the observed difference in response
to Taspase1 inhibition.

Consistent with this notion of “lineage addiction” mediated by broad

epigenetic changes occurring in development (Garraway and Sellers, 2006), Taspase1 regulates
broad-acting transcriptional regulators such as TFIIA and MLL. MLL, in particular, is implicated in
multiple developmental processes and is a key actor in the interplay between the Trithorax and
Polycomb groups of developmental regulators.

MLL deregulation causes global epigenetic

changes and gene expression changes in pathological conditions like cancer (Krivtsov and
Armstrong, 2007). To control for cellular context, and to better understand Taspase1-mediated
regulation of MCL-1, additional glioblastoma and melanoma cell lines should be analyzed for their
sensitivity to Taspase1 loss-induced MCL-1 destabilization.

The role of Taspase1 in the natural history of a tumor

Though we previously established that Taspase1 is required for tumorigenesis in vitro, it
is unclear what function a protease like Taspase1 could play in tumorigenesis. As a
protease with no known signaling role, it is difficult to imagine that simple over-expression
of a protease would confer tumorigenic capabilities, and indeed, over-expression of Taspase1 in
conjunction with established oncogenes in primary MEFs, or supraphysiological expression of
Taspase1 in immortalized NIH/3T3 fibroblasts does not confer a tumor phenotype (Figure 2.2).
However, soft agar colonies from MEFs transformed by co-expression of complementary
oncogenes MYC/RAS

G12V

G12V

, E1A/RAS

G12V

, and DNP53/RAS

, which represent tumorigenic

clones, uniformly express Taspase1 to a much higher level than the non-selected pool of
transformed cells, which include non-tumorigenic clones (Figure 4.3). Furthermore, Taspase1deficient MEFs are resistant to transformation by the same complementary oncogenes. Taken
together, this implies that oncogenic signaling programs, in order to fulfill the requirements of
tumorigenesis, co-opt Taspase1 function to efficiently transform primary cells.
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However, the

mechanism by which Taspase1 is co-opted as well as the effector functions of Taspase1 required
to facilitate tumorigenesis and maintenance await description.

The signals upstream of Taspase1 are still unknown. However, in silico analysis of the Taspase1
promoter indicates that multiple transcription factors bind in a conserved fashion between
humans, mice, and other species. The promoter analysis pipeline (PAP) (Chang et al., 2006)
identified conserved MYC, HIF1-β/ARNT, and forkhead transcription factor sites, among others in
the Taspase1 promoter region (Table 4.1). Additionally, the intracellular domain of NOTCH1, was
found to bind directly to the MYC promoter, resulting in the transactivation of MYC. This opens
up the possibility that NOTCH1 may indirectly regulate Taspase1 through MYC activity, though
MYC binding to the Taspase1 promoter remains to be demonstrated.

In the same study,

intracellular Notch was found to directly bind to the Taspase1 promoter by ChIP-on-chip assay.
Treatment of T-ALL cell lines harboring activating NOTCH1 mutations with a γ-secretase inhibitor
prevented NOTCH1 cleavage, resulting in markedly decreased promoter occupancy by NOTCH1,
and decreased expression of, known targets HES1 and DELTEX1, as well as MYC and TASP1
(Palomero et al., 2006). Indeed, Taspase1 is highly expressed in T-cell lymphomas compared to
other types of blood tumors (Figure 4.5).

Further investigation into the putative

NOTCH1/Taspase1 pathway may reveal mechanistic insight to how Taspase1 is regulated and
further delineate its role in development and cancer.

4.2 Future directions: in vivo studies

Taspase1 is over-expressed in multiple human cancers
In vitro tumorigenesis, using the soft agar assay, revealed that Taspase1 expression is selectively
up-regulated in tumorigenic clones of oncogene pair-transduced MEFs compared to the nonselected pools of cells.

Evidence suggests that this phenomenon holds true in human

tumorigenesis as well. In a murine model of hepatocellular carcinoma (HCC) TASP1 was found
to be a target of the HNF4α transcription factor, which elevated TASP1 transcript in tumors
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compared to transgenic but pre-tumorigenic livers, while primary human HCC exhibited elevated
Taspase1 protein (Niehof and Borlak, 2008). Furthermore, in an analysis of candidate disease
genes for glioblastoma, TASP1 transcript was enriched in glioblastoma but not in normal white
matter (Scrideli et al., 2008). This is consistent with our histological examination of glioblastoma
tumor sections, which exhibited up-regulation of Taspase1 protein in tumor compared to
histologically normal astrocytes from the same patient (Figure 2.6 and 2.15).

Other tumor types were examined by immunofluorescence show similar increase in Taspase1
protein, including in breast (Figure 4.5) and colon adenocarcinomas (Figure 4.6) as well as in
melanomas (Figure 4.7).

Melanoma sections were compared to benign melanocytic nevi to

gauge the difference in Taspase1 expression between benign and malignant melanocytes, using
adjacent keratinocytes to normalize fluorescent signal. In all of the tumors examined, Taspase1
was localized primarily to a sub-nuclear compartment that co-localizes with the C23 marker for
the nucleolus (Figure 4.5, 4.6, and 4.7). This is surprising finding since Taspase1 was initially
isolated from the light membrane and S100 fractions of 293T cells (Hsieh et al., 2003a). In GFPTaspase1 over-expressing SV40-transformed MEFs, Taspase1 is localized diffusely in the
nucleus as well as concentrated in the nucleolus (data not shown). While in tumor sections,
diffuse nuclear staining was in most cases low, and the presence of nucleoli nearly always
accurately predicted the presence of Taspase1. What function Taspase1 plays in the nucleolus
is a matter of active investigation, but possibilities include the processing of nucleolus-restricted
proteolytic targets, cryptic enzymatic activity (for example, activity more akin to its evolutionary
heritage as an asparaginase), or that it may serve as a scaffold for important factors or co-factors
for nucleolar function. Whether Taspase1 activity is regulated is also an open matter, especially
since Taspase1 seems to remain in the nucleolus in most situations, though preliminary evidence
suggests that Taspase1 may re-localize given cellular stresses like DNA damage. Other work
from our laboratory indicates that Taspase1 shares an interaction with DDB1 and DNAPK, further
implicating a role for Taspase1 responsiveness to DNA damage.
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Murine models of tumorigenesis will elucidate mechanisms of Taspase1 addiction in cancer
Examination of publicly available data from primary human samples provides some insight
regarding which tumor types might depend on Taspase1 for continued propagation.

As our

studies demonstrate, high basal Taspase1 expression in tumors correlates with the degree of
their dependence on continued Taspase1 expression. Though squamous carcinomas of the
cervix and of the head and neck have markedly up-regulated Taspase1 expression, tractable
murine models of tumorigenesis exist for blood tumors in which we have evidence that Taspase1
is up-regulated.

This evidence was gathered from a study done by Radich and colleagues

(Radich et al., 2006), which examined gene expression changes based on progression of CML
from its indolent chronic phase, through the accelerated, and terminal blast crisis phases. When
examining Taspase1 expression in CML progression, a pattern emerges—that Taspase1 is
expressed highly specifically in blast crisis cells (Figure 4.8).

Because blast crisis is largely refractory to treatment, and because Taspase1 up-regulation
suggests a developed dependence on its continued expression, we chose to examine its
dependence on Taspase1 because it could potentially be an important tumor maintenance factor
amenable to pharmacological inhibition.

Progression to blast crisis typically involves genetic

alterations that complement the BCR/ABL oncogenic tyrosine kinase translocation, which drives
proliferation through multiple effectors, including RAS and PI3K/AKT. Most secondary mutations
either directly or indirectly inactivate p53 or Rb, which have positive effects on survival and
proliferation. Yet, it is unclear what causes the loss of differentiation observed in blast crisis—
whether it is a proliferative expansion of undifferentiated blasts, or whether there is an active
program causing de-differentiation (Calabretta and Perrotti, 2004). However, there is evidence
that a translocation associated, albeit at low frequency, with blast crisis—NUP98/HOXA9—can
cause both proliferation and differentiation block of primary human CD34+ cells (Takeda et al.,
2006a). When co-expressed with BCR/ABL in primary murine bone marrow, NUP98/HOXA9
causes a short latency, de-differentiated, and transplantable leukemia reminiscent of human blast
crisis (Dash et al., 2002; Neering et al., 2007).

103

We adopted this co-transduction model for our mice, which bear a conditional allele of Taspase1

f/f

as well as Cre-recombinase under the control of an interferon-responsive Mx1 promoter (Mx1f/f

Cre+;Taspase1 ).

Bone marrow from conditional Taspase1 mice as well as control (Mx1-

+/+

Cre+;Taspase1 ) mice were subjected to retroviral transduction with a virus encoding MSCVp210

BCR/ABL

and MSCV-NUP98/HOXA9-IRES EGFP (vectors courtesy of M. Tomasson,

Washington University in Saint Louis) and transplanted into lethally irradiated recipient mice.
Tumor latency for these primary recipients was around 17-21 days.
+

Spleens from primary

+

recipient mice were analyzed for CD34 /c-Kit positive cells as well as absence of differentiated
granulocytic or lymphoid markers (Mac1/Gr1 and B220/CD4/CD8, respectively), and comparable
number of cells sorted for hematopoetic stem cell enriched immunophenotype (HSC, Lin
+

-

+

/Sca1 /Kit ) were injected into sub-lethally irradiated mice to synchronize the onset of disease.
One week after injection, poly-I-C injections were initiated to induce Taspase1 deletion, which
was largely successful, as assessed by PCR genotyping.

We were not able to resolve a survival difference between mice bearing Taspase1 deficient
tumors and control. However, in vitro culture of leukemic blasts from the spleens of the primary
transplant (the same as used for secondary transplant, Figure 4.8) exhibited a decreased ability
for Taspase1 deficient cells to survive in the long term. Murine recombinant interferon β (mIFN-β)
treatment was able to induce Taspase1 deletion in a fraction of cultured blasts, resulting in a
decreased proliferation, increased cell death, and eventual loss of the Taspase1-deficient
population (Figure 4.8). Why there was a significant portion of cells that was not responsive to in
vitro mIFN-β is unclear; however, that it took roughly 35 days for Taspase1-wild type blasts to
fully out-compete Taspase1-null blasts suggests that Taspase1 deficiency causes leukemic
blasts to be disadvantaged but is, alone, not sufficient to cause rapid death or severe proliferative
block.

Though in vitro data shows some anti-cancer effect in leukemic blasts in vitro, the failure to
observe an extension in survival could be due to a variety of reasons. Since Taspase1 deficiency
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does not kill tumor cells rapidly, leukemic blasts may still proliferate sufficiently to overwhelm the
host before a therapeutic effect can take place. Alternatively, the secondary transplant may
reflect a different kind of leukemia between the wild type control and the floxed conditional
Taspase1 leukemia because pools of bone marrow are transduced, with transfection efficiencies
that are roughly 5% for the GFP-tagged NUP98/HOXA9 and less than 0.1% likely transduced
with both BCR/ABL and NUP98/HOXA9. Thus, it is unclear which cell of origin gives rise to the
observed leukemia.

To address the first problem, serial transplant from secondary recipients to tertiary recipients may
help resolve a difference between Taspase1-null leukemias and Taspase1-wild type. As was
observed in cancer cell lines, Taspase1 loss requires additional death stimuli to achieve an
appreciable gain in cell death, and this may be the case in blast crisis leukemias as well. Further
characterization of BCL-2 family members, such as MCL-1 and BIM may provide insight into the
possible molecular regulation of cell death in these cells, since changes in these proteins might
dictate response to therapies like ABT-737 and imatinib. Decreased proliferation may be evident
by staining Taspase1-deficient cells to assess actively cycling cells, while probing for expression
levels of known Taspase1 regulated genes Cyclins D, E, A, and CDKIs p16
KIP1

p27

.

BCR/ABL is known to repress p27

KIP1

INK4C

and p18

INK4A

CIP1

, p21

, and

through activation of the PI3K

pathway (Gesbert et al., 2000), while our prior work demonstrates an inverse relationship
between Taspase1 function and p27 expression.

More recent studies using the BCR/ABL and NUP98/HOXA9 model of blast crisis have taken
measures to ensure the generation of more homogeneous tumors. Using a MSCV-BCR/ABLIRES-GFP co-transduced with MSCV-NUP98/HOXA9-YFP to isolated LSK cells allowed Jordan
and colleagues to track and immunophenotype the leukemia initiating cells in this model as
-

+

+

+

+

-

Lineage /Kit /Flt3 /Sca / CD34 /CD150 that are simultaneously GFP and YFP double positive
(Neering et al., 2007). Transduction of the LSK compartment of bone marrow limits the subtypes
of cells that can give rise to leukemia, decreasing variability in the resultant phenotype.
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4.3 Implications of non-oncogene addiction in cancer therapy

Non-oncogene addiction
Cancer cells exhibit deregulated signaling pathways with adaptations that overcome cellular
safeguards that prevent oncogenic transformation. This “intrinsic tumor suppression” represents
a pleiotropic balancing act seen in much of biology, in this case with aberrant signaling eliciting
biological countermeasures to maintain homeostasis (Lowe et al., 2004).

The product of

tumorigenesis, then, is the phenotypic manifestation of accrued genetic and epigenetic changes
that drive proliferative and survival signals, or that disarm the intrinsic anti-tumor responses. The
phenomenon of oncogene addiction suggests that perturbation of this balance can be
catastrophic for the tumor cell, as the signaling pathways have re-wired themselves through the
natural history of the genesis of the tumor to require persistent signaling to maintain unrestricted,
malignant growth (Weinstein, 2000). Though this is the concept underlying most of the current,
successful targeted therapies, these therapies do not cure cancer, suggesting that just as
cancers can evolve their signaling to accommodate increased proliferative drive against the
balance of growth suppression and cell death, their addictions evolve away from particular apical
oncogenes to other oncogenes that employ shared, or perhaps distinct, subordinate processes.

Lindquist and colleagues described a rate-limiting factor in tumorigenesis—the heat shock factor
1 (HSF1) transcription factor, which is required for efficient tumorigenesis and tumor
maintenance. Deficiency in HSF1 impaired chemical skin carcinogensis as well as a p53-mutant
carcinogenesis in mice and prevented transformation of MEFs by the well-established oncogene
PDGF-B. Human cancer cell lines also depend on HSF1 for continued proliferation and survival,
while normal fibroblasts did not, suggesting an increased reliance on HSF1 in cancer.
Concordantly, HSF1 knockout mice were also overtly normal. Lindquist and colleagues also
demonstrated the involvement of HSF1 in a broad array of biological pathways, including glucose
metabolism, PKA signaling, and protein translation. Importantly, HSF1 over-expression did not
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drive tumorigenesis, which, like Taspase1, excludes it as a classical oncogene (Dai et al., 2007a).
Increased dependence on the normal functions of cellular non-oncogenes like HSF1 was termed
“non-oncogene addiction” (Solimini et al., 2007). Since tumors strongly enforce signaling to many
biological processes, and thus can be thought of as cells in “overdrive,” this potentially implicates
a large number of non-oncogenes which may be rate-limiting in the formation and maintenance of
cancer.

Two classes of non-oncogene addiction, and likely more
The functions of HSF1 serve as a general paradigm for the action of non-oncogene addiction
factors.

As a transcription factor responsive to proteotoxic stress, HSF1 contributes to heat

tolerance through resolution of non-native protein stress. Examination of other putative nononcogene addiction factors formed the basis for postulating two general classes of non-oncogene
addiction—one which, as a result of deficiency in the non-oncogene, lowers the general threshold
of stress resistance in a cell and one that increase cellular stresses to overwhelm the supportive
networks in place to permit the inherently stressful cancer state. Cancers are subjected, by their
nature, to increased genotoxic, proteotoxic, oxidative, and metabolic stresses (Luo et al., 2009).
Causing an imbalance in the stress state, as evidenced by HSF1 loss, can severely impede
tumor growth. Even dietary restriction alone, causing metabolic stress, can hamper growth in
tumors that do not constitutively activate the PI3K pathway (Kalaany and Sabatini, 2009)

Other non-oncogene addiction factors are readily discernable from the increased or altered
normal cellular physiology adopted by the tumor. A recent study demonstrated that ribosomal
haploinsufficiency severely impaired MYC-mediated tumorigenesis.

Many cancers, to

accommodate for increased proliferation and other cellular functions, have increased overall
protein production as well as ribosome biosynthesis. MYC has been described to be a master
regulator of multiple aspects of ribosome biogenesis and translational control (Ruggero and
Pandolfi, 2003). Haploinsufficiency of ribosome subunit L24 caused total protein production to fall
from its elevated state, when driven by MYC, to basal levels, which significantly prolonged the
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latency to development of MYC-driven lymphomas (Barna et al., 2008).

An earlier study

demonstrated, conversely, that increased expression of ribosomal subunit L11 provided a
negative feedback signal that down-regulated MYC activity (Dai et al., 2007b), suggesting that in
abnormally driven states, perturbation of up-regulated normal cellular functions (ribosomal
biogenesis in this case) can have anti-tumor effects.

Perhaps what substantiates the notion that non-oncogene addiction is relevant to cancer therapy
is the clinical success of targeted inhibitors of the proteasome. The proteasome performs the
crucial function of protein turnover to alleviate any potential stress caused by accumulation of
expired proteins, as well as allowing proper execution of biological cascades that depend on the
periodic loss of signaling molecules. Bortezomib, as discussed in Chapter 3, is a dipeptidyl
boronic acid that inhibits the threonine protease function of the proteasome, which elevates the
inhibitor of NF-κB, IκB, to prevent NF-κB-mediated activation of pro-cancer targets, including IL-6,
Cyclin D1, and MYC (Hideshima et al., 2001). Bortezomib has been used with clinical success to
treat multiple myeloma (Shah and Orlowski, 2009) and a newer, cyclic peptide proteasome
inhibitor Argyrin A has been demonstrated to inhibit cancer growth in a p27

KIP1

dependent manner

(Nickeleit et al., 2008).

It is interesting to note that though multiple myelomas exhibit addiction to proteasomal function,
the targets of proteasome inhibition, through stabilizing the majority of cellular proteins, include
both oncogenes as well as tumor suppressors. On the balance, however, proteasome inhibition
exerts an anti-cancer effect. It seems, then, that a third category of non-oncogene addiction
exists—one which depends on the re-activation of latent tumor suppressive mechanisms or
inactivation of oncogenes.

Argyrin A, as mentioned, has anti-cancer effects due to its

stabilization of the cell cycle inhibitor p27, activating a latent tumor suppressor function. IRF4 is
an example of a non-oncogene addiction factor causing the down-regulation of oncogenic
function in multiple myeloma. IRF4 is a transcription factor involved in the maturation of antigenstimulated B-cells to plasma cells. In multiple myeloma, IRF4 was demonstrated to participate in
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a positive feedback cycle with MYC, though the repertoire of its function is broad—ranging from
cell cycle regulation, metabolic control, membrane biogenesis, cell death, and differentiation.
IRF4 depletion breaks this feedback and was lethal to multiple myeloma cells. Consistent with its
role as a non-oncogene addiction factor, its loss had little effect on normal blood cells (Shaffer et
al., 2008; Shaughnessy, 2008).

Taspase1 as a non-oncogene mediator of tumorigenesis and maintenance
Taspase1, much like IRF4, is a non-oncogene addiction factor that regulates tumor suppressor
and oncogene functions. Taspase1 also orchestrates multiple developmental processes through
its proteolytic regulation of MLL, which in turn maintains proper HOX gene expression. Taspase1
targets TFIIA and ALF also are general transcription factors likely involved in other important
developmental processes (S. Sasagawa, unpublished data). This and the possibility that there
are other substrates awaiting description intimates a substantial and complex repertoire of
Taspase1 function. This is in keeping with current non-oncogene factors described, which are
generally transcription factors (IRF4, HSF1) or members of normal cellular machinery with very
general functions (the ribosome and proteasome). It is possible that this is coincidence, or that
too few non-oncogene addiction factors have been validated. Alternatively, there may be some
underlying reason that cells become addicted to these discreet molecular nodes that integrate
broad-ranging inputs and effectors.

It is possible that the plasticity of the inputs and effectors for non-oncogene addiction factors
obviates the need for tumors to select genetic mutants, because these factors are so pliable that
their tumorigenic outputs are but extensions of their normal day jobs.

Though they are

subordinate to oncogene signaling, the transformed state still depends on the continued function
of these pieces of normal cellular machinery and will depend on them to a higher degree than
non-transformed cells. Yet, it may also be an eventuality that cancer, since it is a dynamic and
evolving organism, will find a way to circumvent reliance on non-oncogene addiction factors in a
similar way it divorces itself from apical oncogenes (Merlo et al., 2006). It has been suggested
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then, as demonstrated in the case of Taspase1 inhibition (Figure 2.11), that additional
“orthogonal” treatments will bolster therapeutic effects of non-oncogene addiction targeting (Luo
et al., 2009). To this end, we have demonstrated that DNA damaging agents as well as the BCL2/BCL-XL-targeted chemotherapeutic ABT-737 cooperate strongly with Taspase1-deficiency to kill
the glioblastoma cell line U251 in vitro and in vivo.

Our studies demonstrate that Taspase1 coordinates both proliferation and apoptosis in cancer
cell lines via its regulation of p27

KIP1

and MCL-1, respectively. We have also found that human

tumors over-express Taspase1 likely reflecting an increased reliance on its function. Further, we
show that the bioactive small molecule TASPIN-1 demonstrates specific Taspase1 inhibition and
anti-tumor effects in vitro in breast adenocarcinoma and glioblastoma cell lines, and in vivo in
murine tumor models. Together, this body of work places Taspase1 firmly as a promising drug
target for cancer therapy, warranting further study of Taspase1 regulation and other Taspase1
effector functions, as well as the characterization and modification of new and current Taspase1
inhibitors for therapy in cancer patients.
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4.4 Figures

Figure 4.1. Taspase1 coordinates proliferation and apoptosis through its regulation of Cyclindependent kinase inhibitors (CDKIs), Cyclins, and MCL-1.
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Figure 4.2. Primary MEFs are not sensitized to cell with Taspase1 deficiency.
A, Cell death was determined by Annexin V-Cy3 staining of primary MEFs subjected to various
the following death stimuli – 24h detachment in 1% serum (anoikis), 24h in 100μg/mL etoposide,
and 24h in 2μM doxorubicin. Control cells were adherent cells analyzed 24h after plating. B,
Western blot analysis of pro-apoptotic BH3-only proteins Bid, Bim, and PUMA and anti-apoptotic
MCL-1, BCL-XL, and BCL-2. Equal protein loading was determined by β-Actin immunoblot.
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Figure 4.3. Transformed clones up-regulate Taspase1 expression
A, Primary MEFs were transduced with retroviruses encoding the oncogene pairs indicated.
Immunoblot compares expression of Taspase1 in primary MEFs to oncogene transduced MEFs
prior to soft agar selection. B, Western blot analysis of Taspase1 expression in primary MEFs
compared to clones selected for their survival in soft agar culture.
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A

B

Figure 4.4. Taspase1 expression is up-regulated in subsets of blood tumors.
A, Taspase1 transcript from human leukemias designated by their FAB subtype. B, MLL1
transcript from human leukemias designated by their FAB subtype. Data courtesy of T. Ley and
N. Grieselhuber.

114

Figure 4.5. Taspase1 is over-expressed in human breast cancer.
A, Immunofluorescence analysis of Taspase1 in breast cancer (left panels) and histologically
normal ducts (right panels). Taspase1 was detected using a polyclonal antibody raised against
Taspase1 (DF380, Alexa-488, green), as well as nucleolar antigen C23 (Alexa-568, red), and
DAPI (blue) for nuclei. The top two panels are Taspase1 staining alone, and the bottom two are
merged red, green, and blue images. B, Breast cancer stained with a monoclonal antibody
raised against Taspase1 (9G1D1, Alexa-488, green). Fluorescence intensity was quantified and
compared between histologically normal and tumor tissue within the same section. The mean
intensity is 1.31 (1.19-1.518, 95% CI), where intensity of normal tissue = 1.
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Figure 4.6. Taspase1 is over-expressed in human colon cancer.
Immunofluorescence analysis of Taspase1 in colon cancer was performed using a monoclonal
antibody raised against Taspase1 (10H2F6, Alexa-488, green). Fluorescence intensity was
quantified and compared between histologically normal and tumor tissue within the same section.
The mean intensity is 1.94 (1.34-2.55, 95% CI), where intensity of normal tissue = 1.
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Figure 4.7. Taspase1 is highly expressed in human melanoma.
A, Immunofluorescence analysis of Taspase1 in melanoma was performed using a polyclonal
antibody raised against Taspase1 (DF380, Alexa-488, green). Melan-A was detected using a
monoclonal antibody (Alexa-568, red), and nuclei were visualized by DAPI stain (blue). B, Melan
A staining of malignant melanocytes was performed by immunoperodxidase development of DAB
(brown). Taspase1 was visualized by staining with a monoclonal antibody against Taspase1
(10H2F6, Alexa-488, green).
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Figure 4.8. A murine model for Taspase1-dependence in CML blast crisis.
A, A schematic representation of the blast crisis model, comparing tumors derived from donor
f/f
bone marrow from Mx1-Cre wild type and Taspase1 mice. B, Taspase1 transcript level from a
study of 57 cases of chronic phase CML, 17 cases of accelerated phase, and 37 cases of blast
-9
crisis CML done by Radich, et al. Taspase1 is overexpressed in blast crisis (p=3.45x10 ,
statistics from www.oncomine.org). C, Primary transplant cells were cultured with a 2 day puls of
1000U/mL murine IFN-β in IMDM/15% FBS/50nM β-mercaptoethanol supplemented with
10ng/mL IL-3, 10ng/mL IL-6, and 100ng/mL SCF. Cre-mediated Taspase1 deletion was
assessed by PCR. D, Continued culture of blast crisis cells of indicated treatment and genotype
were counted by Hemavet 950 (Drew Scientific, Dallas, TX). E, Cell death in continuous culture
was determined by trypan blue exclusion.
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Accession
MA0058
M00118
M00118
M00960
M00960
M00799
M00799
M00473
MA0093
MA0059
M00472
M00236

TF name
Max
c-Myc:Max
c-Myc:Max
PR, GR
PR, GR
Myc
Myc
FOXO1
USF
Myc-Max
FOXO4
Arnt

TF gene ID

Symbol

4149
4609
5241
2908
4149
4609
2308
7391
4609
4303
405

MAX
MYC
PGR
NR3C1
MAX
MYC
FOXO1A
USF1
MYC
MLLT7
ARNT

P-value
0.0003
0.0005
0.0005
0.0007
0.0007
0.0009
0.0009
0.002
0.0021
0.0035
0.0036
0.0066

Table 4.1. Promoter analysis pipeline analysis of the Taspase1 promoter.
Promoter analysis pipeline (PAP, http://bioinformatics.wustl.edu/webTools/Home Action.do)
analysis of conserved transcription factor binding sites between mouse and human Taspase1
promoters.
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